{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":749,"total_is_capped":false,"direct_labels_cover":2,"predictions_cover":749,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"640f9589c59b","filters":{"topic":"Melanoma and MAPK Pathways"}},"results":[{"id":"W2128542677","doi":"10.1056/nejmoa1103782","title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7688,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Vemurafenib; Medicine; Dacarbazine; Interim analysis; Internal medicine; Adverse effect; Melanoma; Oncology; Rash; Dabrafenib; Progression-free survival; Nausea; Clinical trial; Cancer research; Metastatic melanoma; Chemotherapy; Cancer","authors":[{"name":"Paul B. Chapman","is_ca":false},{"name":"Axel Hauschild","is_ca":false},{"name":"Caroline Robert","is_ca":false},{"name":"John B.A.G. Haanen","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false},{"name":"James Larkin","is_ca":false},{"name":"Reinhard Dummer","is_ca":false},{"name":"Claus Garbe","is_ca":false},{"name":"Alessandro Testori","is_ca":false},{"name":"Michele Maio","is_ca":false},{"name":"David Hogg","is_ca":true},{"name":"Paul Lorigan","is_ca":false},{"name":"Célèste Lebbé","is_ca":false},{"name":"Thomas Jouary","is_ca":false},{"name":"Dirk Schadendorf","is_ca":false},{"name":"Antoni Ribas","is_ca":false},{"name":"Steven O’Day","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"John M. Kirkwood","is_ca":false},{"name":"Alexander M.M. Eggermont","is_ca":false},{"name":"Brigitte Dréno","is_ca":false},{"name":"K. B. Nolop","is_ca":false},{"name":"Jiang Li","is_ca":false},{"name":"B. Nelson","is_ca":false},{"name":"Jeannie Hou","is_ca":false},{"name":"Richard J. Lee","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false},{"name":"Grant A. McArthur","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0159994996001733,"gpt":0.22066546399615,"spread":0.2046659643959767,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008445873,0.0002372165,0.0004498042,0.000178215,0.0001014512,0.000221148,0.0001882189,0.0001800431,0.00123204],"category_scores_gemma":[0.0009019055,0.00006918138,0.0004808526,0.0001213748,0.0001956896,0.0001876891,0.0002103459,0.0004963441,0.0001206485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002341401,"about_ca_system_score_gemma":0.0002332619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001835926,"about_ca_topic_score_gemma":0.0004021598,"domain_scores_codex":[0.9997167,0.0001430699,0.00001486479,0.0000368608,0.00003864832,0.00004982441],"domain_scores_gemma":[0.9997339,0.00009326206,0.0000810057,0.00001625118,0.00001228661,0.00006329297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.242574,0.01000532,0.08966987,0.001113135,0.00153538,0.0008762745,0.0002969125,0.009980792,0.09372028,0.0003682655,0.002228821,0.547631],"study_design_scores_gemma":[0.04944564,0.3887821,0.5095587,0.0001930126,0.001711291,0.004420728,0.0001552954,0.008731132,0.02496947,0.001350382,0.01062291,0.00005916296],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970224,0.002013559,0.0004095958,0.00009229236,0.00001906105,0.00002770818,0.00005398614,0.00001706524,0.0003443662],"genre_scores_gemma":[0.9988675,0.0005498672,0.0002366564,0.00005676489,0.00002564824,0.00002587409,0.0001219832,0.00000207731,0.0001137537],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00123204,"threshold_uncertainty_score":0.004466653,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128035403","doi":"10.1056/nejmoa1412082","title":"Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5352,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; BC Cancer Agency","funders":"","keywords":"Nivolumab; Melanoma; Mutation; Medicine; Cancer research; Biology; Genetics; Internal medicine; Cancer; Immunotherapy; Gene","authors":[{"name":"Caroline Robert","is_ca":false},{"name":"Georgina V. Long","is_ca":false},{"name":"Benjamin Brady","is_ca":false},{"name":"Caroline Dutriaux","is_ca":false},{"name":"Michele Maio","is_ca":false},{"name":"Laurent Mortier","is_ca":false},{"name":"Jessica C. Hassel","is_ca":false},{"name":"Piotr Rutkowski","is_ca":false},{"name":"Catriona M. McNeil","is_ca":false},{"name":"Ewa Kalinka‐Warzocha","is_ca":false},{"name":"Kerry J. Savage","is_ca":true},{"name":"Micaela Hernberg","is_ca":false},{"name":"Célèste Lebbé","is_ca":false},{"name":"J. Charles","is_ca":false},{"name":"Catalin Mihalcioiu","is_ca":true},{"name":"Vanna Chiarion‐Sileni","is_ca":false},{"name":"Cornelia Mauch","is_ca":false},{"name":"Francesco Cognetti","is_ca":false},{"name":"Ana Arance","is_ca":false},{"name":"Henrik Schmidt","is_ca":false},{"name":"Dirk Schadendorf","is_ca":false},{"name":"Helen Gogas","is_ca":false},{"name":"L. Lundgren-Eriksson","is_ca":false},{"name":"Christine E. Horak","is_ca":false},{"name":"Brian J. Sharkey","is_ca":false},{"name":"Ian M. Waxman","is_ca":false},{"name":"Victoria Atkinson","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007510965650476341,"gpt":0.2337536327064622,"spread":0.2262426670559859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007376366,0.000277766,0.0007465404,0.0001836775,0.0002439682,0.0002824135,0.0002332486,0.0003066311,0.0009415374],"category_scores_gemma":[0.001089824,0.0001603368,0.0004362279,0.0001504678,0.0002941495,0.0002028328,0.0001453203,0.0007969536,0.0001808042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005873333,"about_ca_system_score_gemma":0.000537871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008822759,"about_ca_topic_score_gemma":0.002663008,"domain_scores_codex":[0.999634,0.000190632,0.00002448087,0.00006098332,0.00004165743,0.00004816914],"domain_scores_gemma":[0.9995321,0.0001834679,0.0001146618,0.00002076464,0.00002023998,0.0001288373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4628668,0.01344368,0.09139571,0.001821029,0.002335471,0.001585963,0.0006070859,0.007129424,0.07233088,0.0004968912,0.003152635,0.3428344],"study_design_scores_gemma":[0.1911449,0.541446,0.2156497,0.0005669704,0.002224719,0.00368156,0.0003495796,0.00755629,0.01820043,0.00115424,0.01793935,0.00008628311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958852,0.003035152,0.0001290559,0.0001228843,0.00005674901,0.0001118835,0.00003932832,0.000008558362,0.0006111139],"genre_scores_gemma":[0.9978768,0.001175632,0.0002344928,0.0001750309,0.00007036557,0.00008517702,0.00007548735,0.000004179808,0.0003028206],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009415374,"threshold_uncertainty_score":0.004261374,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2107495112","doi":"10.1128/mmbr.00031-10","title":"Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases","year":2011,"lang":"en","type":"review","venue":"Microbiology and Molecular Biology Reviews","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3257,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Kinase; Biology; Cell biology; MAPK/ERK pathway; p38 mitogen-activated protein kinases; Ribosomal s6 kinase; Mitogen-activated protein kinase; Protein kinase A; Mitogen-activated protein kinase kinase; MAP2K7; MAP kinase kinase kinase; ASK1; Signal transduction; Cyclin-dependent kinase 2; P70-S6 Kinase 1; Protein kinase B","authors":[{"name":"Marie Cargnello","is_ca":true},{"name":"Philippe P. Roux","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02984821007226111,"gpt":0.2585359077245694,"spread":0.2286876976523083,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005619389,0.0008513291,0.000410203,0.0006948559,0.0007600521,0.001675086,0.0004390077,0.0006760081,0.003942874],"category_scores_gemma":[0.0007370327,0.0002542977,0.0004752312,0.0007170089,0.0005439934,0.001481325,0.000711845,0.001105636,0.002616903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007503229,"about_ca_system_score_gemma":0.000966107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006554502,"about_ca_topic_score_gemma":0.0004287074,"domain_scores_codex":[0.9995512,0.00005495243,0.00004400242,0.0001261336,0.0001594268,0.00006423517],"domain_scores_gemma":[0.9997538,0.00002035167,0.00007937815,0.00001440549,0.00008763256,0.00004450941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001017717,0.0003928366,0.009639783,0.005788635,0.0002376343,0.001937393,0.0004935067,0.001974556,0.6377046,0.04055309,0.02391461,0.2763457],"study_design_scores_gemma":[0.0001008302,0.0007030778,0.04571405,0.0009126298,0.0002400899,0.009832817,0.0008289524,0.003522419,0.2857821,0.02696613,0.6252052,0.0001917474],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2215709,0.6241094,0.0609168,0.006526245,0.00296879,0.0005202186,0.006723506,0.001002826,0.07566126],"genre_scores_gemma":[0.6988566,0.2355357,0.02179215,0.001434642,0.001495383,0.0003303413,0.003796388,0.0001198283,0.03663882],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003942874,"threshold_uncertainty_score":0.01319021,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166262263","doi":"10.1016/s0140-6736(12)60868-x","title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2960,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"GlaxoSmithKline","keywords":"Dabrafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Hazard ratio; Clinical endpoint; Adverse effect; Oncology; Phases of clinical research; Progression-free survival; Clinical trial; Randomized controlled trial; Gastroenterology; Surgery; Metastatic melanoma; Chemotherapy; Cancer; Vemurafenib; Confidence interval; Cancer research","authors":[{"name":"Axel Hauschild","is_ca":false},{"name":"Jean‐Jacques Grob","is_ca":false},{"name":"Lev Demidov","is_ca":false},{"name":"Thomas Jouary","is_ca":false},{"name":"Ralf Gutzmer","is_ca":false},{"name":"Michael Millward","is_ca":false},{"name":"Piotr Rutkowski","is_ca":false},{"name":"Christian U. Blank","is_ca":false},{"name":"Wilson H. Miller","is_ca":true},{"name":"Eckhart Kaempgen","is_ca":false},{"name":"Salvador Martín‐Algarra","is_ca":false},{"name":"Bogusława Karaszewska","is_ca":false},{"name":"Cornelia Mauch","is_ca":false},{"name":"Vanna Chiarion‐Sileni","is_ca":false},{"name":"Anne-Marie Martin","is_ca":false},{"name":"S. Swann","is_ca":false},{"name":"Patricia Haney","is_ca":false},{"name":"Beloo Mirakhur","is_ca":false},{"name":"Mary Guckert","is_ca":false},{"name":"Vicki Goodman","is_ca":false},{"name":"Paul B. Chapman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05743917274431475,"gpt":0.3392784182895699,"spread":0.2818392455452552,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001910806,0.002338361,0.003907179,0.0003788381,0.0004019862,0.001359114,0.0007950622,0.001760307,0.006919031],"category_scores_gemma":[0.001928364,0.0006765875,0.003014379,0.0005694974,0.001027863,0.001218253,0.0004155621,0.003091379,0.001062288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001146219,"about_ca_system_score_gemma":0.001023149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001832075,"about_ca_topic_score_gemma":0.004288086,"domain_scores_codex":[0.9992804,0.0003764146,0.00003670713,0.0001164286,0.00005032648,0.0001398488],"domain_scores_gemma":[0.9992912,0.0002016753,0.0001570873,0.00005695591,0.00005337944,0.0002396788],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9805256,0.001041153,0.0004620246,0.001060389,0.001895935,0.00005918761,0.00003644458,0.0003910434,0.001873811,0.000132373,0.001576502,0.01094555],"study_design_scores_gemma":[0.9840518,0.01310418,0.0009076378,0.00004604607,0.0006189765,0.00004051625,0.00001977099,0.000210248,0.0001218142,0.0001894797,0.0006753111,0.00001422721],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9521987,0.0296333,0.001939182,0.003499237,0.001968201,0.004019842,0.003185037,0.0002624988,0.003294024],"genre_scores_gemma":[0.9695686,0.0119523,0.002314817,0.003066847,0.000713717,0.003937231,0.002279461,0.00005904748,0.00610787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006919031,"threshold_uncertainty_score":0.02314645,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3036759197","doi":"10.1038/s41580-020-0255-7","title":"ERK signalling: a master regulator of cell behaviour, life and fate","year":2020,"lang":"en","type":"review","venue":"Nature Reviews Molecular Cell Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1202,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Cell biology; MAPK/ERK pathway; Kinase; Biology; Cell growth; Cell fate determination; Extracellular; Cell; Signal transduction; Intracellular; Protein kinase A; Cell signaling; Regulator; Cell metabolism; Biochemistry; Transcription factor","authors":[{"name":"Hugo Lavoie","is_ca":true},{"name":"Jessica K. Gagnon","is_ca":true},{"name":"Marc Therrien","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02423147105711939,"gpt":0.280338448925497,"spread":0.2561069778683777,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006779174,0.001158703,0.001195714,0.001343168,0.0002215938,0.001446518,0.0008510035,0.001360344,0.003098384],"category_scores_gemma":[0.000569267,0.0003219217,0.000253921,0.001684987,0.0007393989,0.001569181,0.0009154733,0.0025911,0.002652771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009971728,"about_ca_system_score_gemma":0.001273119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000901896,"about_ca_topic_score_gemma":0.002324972,"domain_scores_codex":[0.999842,0.00001780809,0.00001644724,0.0000275142,0.00007254101,0.00002361147],"domain_scores_gemma":[0.9997659,0.00007952331,0.00003187128,0.000007055592,0.00007261868,0.00004306899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001519524,0.00003853077,0.00009641658,0.00696549,0.00005931103,0.0001223771,0.00002941159,0.0005648852,0.004290111,0.005990103,0.05789797,0.9237933],"study_design_scores_gemma":[0.0000259588,0.0000401364,0.0004621004,0.0009878427,0.00005360492,0.0003647911,0.00003226517,0.0001232762,0.000817084,0.002895577,0.9941826,0.00001472599],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001182575,0.9968998,0.000266703,0.0007016849,0.0005488617,0.000004586245,0.00003211714,0.00001431625,0.001413608],"genre_scores_gemma":[0.0007201227,0.9971386,0.0001723497,0.0003625099,0.0003384995,0.000006104544,0.00004520328,0.000002057557,0.00121463],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003098384,"threshold_uncertainty_score":0.01036519,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1983833034","doi":"10.1038/sj.onc.1210414","title":"The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition","year":2007,"lang":"en","type":"review","venue":"Oncogene","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1104,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Biology; Cell biology; Cell cycle; MAPK/ERK pathway; Kinase; Protein kinase A; Cyclin-dependent kinase 2; Mitogen-activated protein kinase; Signal transduction; Cyclin; Cyclin-dependent kinase 4; Anti-apoptotic Ras signalling cascade; ASK1; Cell growth; Mitogen-Activated Protein Kinase 3; Mitogen-activated protein kinase kinase; Cell; Biochemistry","authors":[{"name":"Sylvain Meloche","is_ca":true},{"name":"Jacques Pouysségur","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04216164765805923,"gpt":0.3239142138717571,"spread":0.2817525662136978,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005172964,0.001335317,0.001311521,0.001458778,0.0003034573,0.001056302,0.001205248,0.001278698,0.002409104],"category_scores_gemma":[0.0003985955,0.0003390591,0.000291524,0.002077804,0.0006208502,0.001512019,0.0006127558,0.002394505,0.003164446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009445853,"about_ca_system_score_gemma":0.001155365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009472421,"about_ca_topic_score_gemma":0.00237434,"domain_scores_codex":[0.9998811,0.00001306307,0.00001455899,0.00002392306,0.0000526743,0.00001464439],"domain_scores_gemma":[0.9998063,0.00005752266,0.00003233444,0.000006412293,0.00006737611,0.00003009134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001794906,0.00008048148,0.0001508659,0.007593885,0.00006647881,0.000385312,0.00003848573,0.0005728679,0.007652795,0.00534134,0.05191079,0.9260273],"study_design_scores_gemma":[0.00002527891,0.00004584623,0.0004308882,0.0007211462,0.00005745488,0.0008756343,0.00002853896,0.0001128346,0.001408361,0.001767777,0.994513,0.00001330937],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001416609,0.9972261,0.0003419827,0.0003787184,0.0005253748,0.000005590839,0.00001893289,0.0000121587,0.001349513],"genre_scores_gemma":[0.000752504,0.9967743,0.0004205401,0.0002433398,0.0003378354,0.000007667034,0.00004249679,0.000002206792,0.00141914],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002409104,"threshold_uncertainty_score":0.008059263,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2155461614","doi":"10.1056/nejmoa1105358","title":"<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1028,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"University of California, San Francisco; Plexxikon; European Organisation for Research and Treatment of Cancer; Jonsson Cancer Center Foundation; National Cancer Institute; University of California, Los Angeles; Cancer Research UK; Wellcome Trust; California Institute of Technology","keywords":"HRAS; Vemurafenib; Neuroblastoma RAS viral oncogene homolog; KRAS; Cancer research; MAPK/ERK pathway; Carcinogenesis; V600E; Cell growth; Mutation; Biology; Medicine; Kinase; Melanoma; Cancer; Internal medicine; Gene; Genetics","authors":[{"name":"Fei Su","is_ca":false},{"name":"Amaya Virós","is_ca":true},{"name":"Carla Milagre","is_ca":true},{"name":"Kerstin Trunzer","is_ca":false},{"name":"Gideon Bollag","is_ca":false},{"name":"Olivia Spleiss","is_ca":false},{"name":"Jorge S. Reis‐Filho","is_ca":true},{"name":"Xiangju Kong","is_ca":false},{"name":"Richard C. Koya","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false},{"name":"Paul B. Chapman","is_ca":false},{"name":"Min Jung Kim","is_ca":false},{"name":"Robert Hayward","is_ca":true},{"name":"Matthew J. Martin","is_ca":true},{"name":"Hong Yang","is_ca":false},{"name":"Qiongqing Wang","is_ca":false},{"name":"Holly Hilton","is_ca":false},{"name":"Julie S. Hang","is_ca":false},{"name":"Johannes Noé","is_ca":false},{"name":"Maryou Lambros","is_ca":true},{"name":"Felipe C. Geyer","is_ca":true},{"name":"Nathalie Dhomen","is_ca":true},{"name":"Ion Niculescu‐Duvaz","is_ca":true},{"name":"Alfonso Zambon","is_ca":true},{"name":"Dan Niculescu‐Duvaz","is_ca":true},{"name":"Natasha Preece","is_ca":true},{"name":"Lídia Robert","is_ca":false},{"name":"Nicholas Otte","is_ca":false},{"name":"Stephen Mok","is_ca":false},{"name":"Damien Kee","is_ca":false},{"name":"Yan Ma","is_ca":false},{"name":"Chao Zhang","is_ca":false},{"name":"Gaston Habets","is_ca":false},{"name":"Elizabeth A. Burton","is_ca":false},{"name":"Bernice H. Wong","is_ca":false},{"name":"Hoa Nguyen","is_ca":false},{"name":"Mark Kockx","is_ca":false},{"name":"Luc Andries","is_ca":false},{"name":"Brian Lestini","is_ca":false},{"name":"K. B. Nolop","is_ca":false},{"name":"Richard J. Lee","is_ca":false},{"name":"Andrew K. Joe","is_ca":false},{"name":"James L. Troy","is_ca":false},{"name":"René González","is_ca":false},{"name":"Thomas E. Hutson","is_ca":false},{"name":"Igor Puzanov","is_ca":false},{"name":"Bartosz Chmielowski","is_ca":false},{"name":"Caroline J. Springer","is_ca":true},{"name":"Grant A. McArthur","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"Roger S. Lo","is_ca":false},{"name":"Antoni Ribas","is_ca":false},{"name":"Richard Marais","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006657930907524172,"gpt":0.2093037642751884,"spread":0.2026458333676642,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002410953,0.0001630761,0.0003192322,0.0006626778,0.0003570332,0.0004671448,0.0001600045,0.0004098856,0.001377456],"category_scores_gemma":[0.001083777,0.0001678807,0.0003090043,0.0005159294,0.0001809951,0.0002572438,0.0001850132,0.0003427819,0.0001936499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002028219,"about_ca_system_score_gemma":0.0001837148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000807571,"about_ca_topic_score_gemma":0.001003079,"domain_scores_codex":[0.9997759,0.00003896609,0.00002995951,0.00005430391,0.00005922764,0.00004165865],"domain_scores_gemma":[0.99943,0.0001213208,0.0002394934,0.00002580133,0.00006852355,0.0001149157],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003987118,0.00003958001,0.9922442,0.00001492442,0.00004059869,0.0008545634,0.00003768034,0.00005753049,0.003135949,0.00001069806,0.00008027378,0.003085218],"study_design_scores_gemma":[0.00001553987,0.0002143097,0.9940394,0.000007164177,0.00005178945,0.004412049,0.00009371947,0.0002194212,0.0006727151,0.00001879735,0.0002512662,0.000003847345],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989256,0.0003773279,0.00004755204,0.00002836303,0.000004401794,0.000007079899,0.00006995678,0.000005196082,0.0005344561],"genre_scores_gemma":[0.9997713,0.00007155017,0.00003944873,0.00001415102,0.000005494788,0.00000305142,0.00005427839,0.00000105745,0.0000397007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001377456,"threshold_uncertainty_score":0.004608095,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111404068","doi":"10.1016/s1470-2045(14)70012-9","title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":978,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; F. Hoffmann-La Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Population; Oncology; Progression-free survival; Metastatic melanoma; Chemotherapy; Cancer research; Cancer","authors":[{"name":"Grant A. McArthur","is_ca":false},{"name":"Paul B. Chapman","is_ca":false},{"name":"Caroline Robert","is_ca":false},{"name":"James Larkin","is_ca":false},{"name":"John B.A.G. Haanen","is_ca":false},{"name":"Reinhard Dummer","is_ca":false},{"name":"Antoni Ribas","is_ca":false},{"name":"David Hogg","is_ca":true},{"name":"Omid Hamid","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false},{"name":"Claus Garbe","is_ca":false},{"name":"Alessandro Testori","is_ca":false},{"name":"Michele Maio","is_ca":false},{"name":"Paul Lorigan","is_ca":false},{"name":"Célèste Lebbé","is_ca":false},{"name":"Thomas Jouary","is_ca":false},{"name":"Dirk Schadendorf","is_ca":false},{"name":"S. O'Day","is_ca":false},{"name":"John M. Kirkwood","is_ca":false},{"name":"Alexander M.M. Eggermont","is_ca":false},{"name":"Brigitte Dréno","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false},{"name":"Ming Yin","is_ca":false},{"name":"Ivor Caro","is_ca":false},{"name":"Suzanne Cheng","is_ca":false},{"name":"Kerstin Trunzer","is_ca":false},{"name":"Axel Hauschild","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0286159142605539,"gpt":0.3339014764236995,"spread":0.3052855621631456,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003949154,0.001826263,0.003658735,0.0004176501,0.0004627716,0.001810358,0.001102231,0.002035602,0.003582321],"category_scores_gemma":[0.002927694,0.0008570632,0.003841465,0.0004780108,0.001255677,0.002123655,0.0004808018,0.004416535,0.001153335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001321256,"about_ca_system_score_gemma":0.0009583288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009440455,"about_ca_topic_score_gemma":0.001521477,"domain_scores_codex":[0.9987283,0.0006131897,0.00006362491,0.0001620243,0.0001274831,0.0003054112],"domain_scores_gemma":[0.9979856,0.0005695259,0.0004997528,0.0002264808,0.0001319271,0.0005866196],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9567642,0.003857563,0.002038258,0.0004802949,0.001854866,0.00007925976,0.00008827834,0.0008627842,0.005060294,0.00008658344,0.001124001,0.02770358],"study_design_scores_gemma":[0.8063305,0.1664794,0.0206879,0.00007640621,0.001679424,0.0002263101,0.0000783322,0.0009554772,0.001380702,0.0004578911,0.001575633,0.00007200619],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916729,0.004752457,0.0004626338,0.0004093361,0.0001912818,0.0004646235,0.000985936,0.00008585576,0.0009748869],"genre_scores_gemma":[0.9937229,0.001502167,0.0004907216,0.000620322,0.0002330184,0.0006096335,0.001358075,0.00003562452,0.001427588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003949154,"threshold_uncertainty_score":0.02088535,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985928174","doi":"10.1038/nature13121","title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","year":2014,"lang":"en","type":"article","venue":"Nature","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":910,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Melanoma; Cancer research; Vemurafenib; V600E; MEK inhibitor; Epidermal growth factor receptor; MAPK/ERK pathway; EGFR inhibitors; Selumetinib; Biology; Medicine; Oncogene; Kinase; Cancer; Mutation; Internal medicine; Cell cycle; Cell biology","authors":[{"name":"Chong Sun","is_ca":false},{"name":"Liqin Wang","is_ca":false},{"name":"Sidong Huang","is_ca":false},{"name":"Guus J.J.E. Heynen","is_ca":false},{"name":"Anirudh Prahallad","is_ca":false},{"name":"Caroline Robert","is_ca":false},{"name":"John B.A.G. Haanen","is_ca":false},{"name":"Christian U. Blank","is_ca":false},{"name":"Jelle Wesseling","is_ca":false},{"name":"Stefan M. Willems","is_ca":false},{"name":"Davide Zecchin","is_ca":false},{"name":"Sebastijan Hobor","is_ca":false},{"name":"Prashanth Kumar Bajpe","is_ca":false},{"name":"Cor Lieftink","is_ca":false},{"name":"Christina Mateus","is_ca":false},{"name":"Stéphan Vagner","is_ca":false},{"name":"Wipawadee Grernrum","is_ca":false},{"name":"Ingrid Hofland","is_ca":false},{"name":"Andreas Schlicker","is_ca":false},{"name":"Lodewyk F.A. Wessels","is_ca":false},{"name":"Roderick L. Beijersbergen","is_ca":false},{"name":"Alberto Bardelli","is_ca":false},{"name":"Federica Di Nicolantonio","is_ca":false},{"name":"Alexander M.M. Eggermont","is_ca":false},{"name":"René Bernards","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.004767629710370415,"gpt":0.2128412747391986,"spread":0.2080736450288282,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001956684,0.0001835566,0.0001575973,0.0001704001,0.0001020337,0.000265655,0.0003043657,0.000258503,0.001590456],"category_scores_gemma":[0.0001760552,0.0001466823,0.0002028848,0.00009334991,0.000205994,0.000215656,0.0001851288,0.0006348835,0.0002430395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003666668,"about_ca_system_score_gemma":0.0001439315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003567557,"about_ca_topic_score_gemma":0.000524926,"domain_scores_codex":[0.9998883,0.00001929058,0.000006773706,0.00001789331,0.00003737246,0.00003027273],"domain_scores_gemma":[0.9999443,0.000009925309,0.00001404453,0.00001752886,0.000006192966,0.000007947975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001856972,0.00005325856,0.0003082888,0.00004710341,0.000009230526,0.0001306357,0.00001467065,0.0004856201,0.9889825,0.001554284,0.0001745006,0.00805434],"study_design_scores_gemma":[0.00005008497,0.0008515451,0.00741089,0.000009434031,0.00001810653,0.0008915206,0.00003014903,0.001791073,0.9822692,0.001035579,0.005632606,0.000009861421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861487,0.004331795,0.002725759,0.0003009567,0.00006782478,0.00003134958,0.0001698051,0.0001970997,0.006026688],"genre_scores_gemma":[0.9967005,0.0009406428,0.0003836377,0.00003895938,0.000009349886,0.000008832747,0.00006327955,0.00001199105,0.001842835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001590456,"threshold_uncertainty_score":0.005320609,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2620651944","doi":"10.1016/s1470-2045(17)30429-1","title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":775,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Medicine; Melanoma; Asymptomatic; Clinical endpoint; Oncology; MEK inhibitor; Internal medicine; Brain metastasis; Phases of clinical research; Clinical trial; Metastatic melanoma; Cancer; Metastasis; Vemurafenib; Cancer research; Biology; MAPK/ERK pathway","authors":[{"name":"Michael A. Davies","is_ca":false},{"name":"Philippe Saïag","is_ca":false},{"name":"Caroline Robert","is_ca":false},{"name":"Jean‐Jacques Grob","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false},{"name":"Ana Arance","is_ca":false},{"name":"Vanna Chiarion‐Sileni","is_ca":false},{"name":"L. Thomas","is_ca":false},{"name":"Thierry Lesimple","is_ca":false},{"name":"Laurent Mortier","is_ca":false},{"name":"Stergios J. Moschos","is_ca":false},{"name":"David Hogg","is_ca":true},{"name":"Iván Márquez‐Rodas","is_ca":false},{"name":"Michele Del Vecchio","is_ca":false},{"name":"Célèste Lebbé","is_ca":false},{"name":"Nicolás Meyer","is_ca":false},{"name":"Ying Zhang","is_ca":false},{"name":"Yingjie Huang","is_ca":false},{"name":"Bijoyesh Mookerjee","is_ca":false},{"name":"Georgina V. Long","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06803476530507808,"gpt":0.3693754023310494,"spread":0.3013406370259713,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001073894,0.001930514,0.002083973,0.0003013558,0.0003264059,0.00123217,0.0006258771,0.001277471,0.004048687],"category_scores_gemma":[0.0008114746,0.0005579659,0.001752866,0.0003839065,0.0006614232,0.001190586,0.0003046026,0.002870369,0.0009952836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001021348,"about_ca_system_score_gemma":0.0008634322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001367297,"about_ca_topic_score_gemma":0.004532118,"domain_scores_codex":[0.9997092,0.0001224315,0.00001192541,0.0000517012,0.00002082256,0.00008385973],"domain_scores_gemma":[0.9996464,0.000062201,0.0000697324,0.00002722634,0.00002484214,0.000169678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9135118,0.005962158,0.00209827,0.001037104,0.002384623,0.0001388161,0.0001328887,0.001422704,0.008270795,0.0002852314,0.004287895,0.06046773],"study_design_scores_gemma":[0.9286817,0.06172111,0.004618043,0.00004854617,0.0007248264,0.0001944796,0.00006409946,0.0008643386,0.0006746161,0.0003620858,0.002010925,0.00003526246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866635,0.006475767,0.0005005918,0.001180743,0.0003811488,0.001170651,0.001559581,0.0001306204,0.001937316],"genre_scores_gemma":[0.9860643,0.004207412,0.001138431,0.001179339,0.0002566124,0.001212184,0.002240062,0.0000364012,0.003665228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004048687,"threshold_uncertainty_score":0.01354414,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165575701","doi":"10.1016/j.cell.2012.02.053","title":"Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":744,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research","keywords":"Kinome; Triple-negative breast cancer; MEK inhibitor; Biology; Cancer research; MAPK/ERK pathway; Reprogramming; Receptor tyrosine kinase; Kinase; Trametinib; Gene knockdown; Cancer; Cell biology; Breast cancer; Apoptosis; Biochemistry; Cell; Genetics","authors":[{"name":"Martin C. Whittle","is_ca":false},{"name":"Kazuhiro Nakamura","is_ca":false},{"name":"Amy N. Abell","is_ca":false},{"name":"Alicia A. Midland","is_ca":false},{"name":"Jon S. Zawistowski","is_ca":false},{"name":"Nancy L. Johnson","is_ca":false},{"name":"Deborah A. Granger","is_ca":false},{"name":"Nicole Vincent Jordan","is_ca":false},{"name":"David B. Darr","is_ca":false},{"name":"Jerry Usary","is_ca":false},{"name":"Pei Fen Kuan","is_ca":false},{"name":"David M. Smalley","is_ca":false},{"name":"Xiaping He","is_ca":false},{"name":"Katherine A. Hoadley","is_ca":false},{"name":"Bing Zhou","is_ca":false},{"name":"Norman E. Sharpless","is_ca":false},{"name":"Charles M. Perou","is_ca":false},{"name":"William Y. Kim","is_ca":false},{"name":"Shawn M. Gomez","is_ca":false},{"name":"Xin Chen","is_ca":false},{"name":"Jian Jin","is_ca":false},{"name":"Stephen V. Frye","is_ca":false},{"name":"H. Shelton Earp","is_ca":false},{"name":"Lee M. Graves","is_ca":false},{"name":"Gary L. Johnson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007236532849522338,"gpt":0.2387321196060584,"spread":0.2314955867565361,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007144449,0.0001113787,0.0001925654,0.0001389078,0.0001590823,0.000332918,0.0001240079,0.000143167,0.001373749],"category_scores_gemma":[0.00009470795,0.00009635017,0.000112447,0.0001289981,0.0001223135,0.0001710496,0.0001297843,0.0003378596,0.0002050898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000362615,"about_ca_system_score_gemma":0.0001691869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001234564,"about_ca_topic_score_gemma":0.002290696,"domain_scores_codex":[0.9999286,0.000008146026,0.000004301645,0.00001134143,0.00002090755,0.00002681934],"domain_scores_gemma":[0.9999694,0.000005497775,0.000006331751,0.000004708366,0.000003777953,0.00001035639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000215436,0.00001726756,0.0002826357,0.00001794803,0.000003441144,0.00007524567,0.00002049639,0.0000911996,0.9975213,0.0001276942,0.00009616223,0.001531007],"study_design_scores_gemma":[0.00002439274,0.0002236137,0.02264794,0.000005482056,0.00001939971,0.0005328966,0.000194653,0.001695273,0.9711667,0.0002018934,0.003277614,0.00001013453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968771,0.0008420456,0.0004040753,0.00008237952,0.00001891638,0.000007016744,0.0002455892,0.00003024057,0.001492708],"genre_scores_gemma":[0.9984984,0.0002640329,0.000158439,0.00002768111,0.000001997211,0.000008092044,0.0001004502,0.000004753081,0.0009360185],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001373749,"threshold_uncertainty_score":0.004595637,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2054946171","doi":"10.1038/nrm3979","title":"Regulation of RAF protein kinases in ERK signalling","year":2015,"lang":"en","type":"review","venue":"Nature Reviews Molecular Cell Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":702,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université du Québec à Montréal; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Kinase; Allosteric regulation; MAPK/ERK pathway; Signalling; Cell biology; Function (biology); Suppressor; Phosphorylation; Chemistry; Biology; Biochemistry; Enzyme; Cancer; Genetics","authors":[{"name":"Hugo Lavoie","is_ca":true},{"name":"Marc Therrien","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02828340218594011,"gpt":0.317174288496513,"spread":0.2888908863105729,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000679295,0.0009460124,0.001022576,0.001277524,0.0002748925,0.001145268,0.0009448931,0.001135447,0.002065269],"category_scores_gemma":[0.0004762824,0.000369394,0.0003414352,0.001300538,0.0008526946,0.001556009,0.00107266,0.002301154,0.001866031],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008009673,"about_ca_system_score_gemma":0.000803198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006163022,"about_ca_topic_score_gemma":0.00146648,"domain_scores_codex":[0.9998268,0.00002196824,0.00001826684,0.00002881825,0.00007574834,0.00002832296],"domain_scores_gemma":[0.9998457,0.00005398249,0.00002592481,0.000006961017,0.00004570638,0.00002165615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001672656,0.00006123407,0.0001665661,0.0100996,0.00008808613,0.0004172782,0.00007730591,0.0009038386,0.01408679,0.01498908,0.03190672,0.9270361],"study_design_scores_gemma":[0.00002954129,0.00004400527,0.0007338623,0.001465346,0.0000715244,0.0008071751,0.00005235297,0.0001856343,0.003202494,0.006211831,0.9871705,0.00002572233],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001850029,0.9976155,0.0003234567,0.0003800581,0.000289424,0.000003825402,0.0000161112,0.000009832418,0.001176887],"genre_scores_gemma":[0.001549855,0.9969272,0.0002306942,0.0002374659,0.0002120176,0.000005586537,0.00002480923,0.000001504921,0.0008109006],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002065269,"threshold_uncertainty_score":0.006909013,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137723371","doi":"10.1200/jco.2007.12.7837","title":"Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":700,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Internal medicine; Clinical trial; Oncology; Multivariate analysis; Progression-free survival; Clinical endpoint; Cancer; Randomized controlled trial; Overall survival","authors":[{"name":"Edward L. Korn","is_ca":false},{"name":"Ping-Yu Liu","is_ca":false},{"name":"Sandra J. Lee","is_ca":false},{"name":"J. W. Chapman","is_ca":false},{"name":"Donna Niedzwiecki","is_ca":false},{"name":"Vera J. Suman","is_ca":false},{"name":"James Moon","is_ca":false},{"name":"Vernon K. Sondak","is_ca":false},{"name":"Michael B. Atkins","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":false},{"name":"Wendy R. Parulekar","is_ca":false},{"name":"Svetomir N. Markovic","is_ca":false},{"name":"Scott Saxman","is_ca":false},{"name":"John M. Kirkwood","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3381739698257792,"gpt":0.5079362980495256,"spread":0.1697623282237464,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.1546557,0.003967302,0.0180566,0.006574961,0.0006282796,0.004705305,0.002883976,0.002231181,0.001602315],"category_scores_gemma":[0.1953109,0.001268384,0.03879759,0.006462581,0.0008322761,0.002644974,0.00162358,0.002842288,0.000177116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001983556,"about_ca_system_score_gemma":0.002332958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002340381,"about_ca_topic_score_gemma":0.003541159,"domain_scores_codex":[0.8516355,0.1245735,0.01027441,0.006357897,0.006479593,0.0006790564],"domain_scores_gemma":[0.7406449,0.2180333,0.02174997,0.01348359,0.004776265,0.001312076],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.005643854,0.00002604312,0.01945659,0.0123952,0.9477602,0.00007915434,0.00004278339,0.004632857,0.0002059689,0.0003090562,0.0008795782,0.008568695],"study_design_scores_gemma":[0.003514076,0.001133027,0.02095403,0.003645872,0.9569032,0.0001634644,0.00005915211,0.007628096,0.0004331524,0.00232062,0.003185413,0.00005983716],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.08072662,0.8727956,0.03533695,0.001621301,0.001331421,0.002515541,0.003000632,0.0004889793,0.002182992],"genre_scores_gemma":[0.9193426,0.04846986,0.02068052,0.001919591,0.0009615979,0.004510328,0.003126444,0.000312666,0.0006764221],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.9819434,"threshold_uncertainty_score":0.8179075,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789665281","doi":"10.1038/s41388-018-0171-x","title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","year":2018,"lang":"en","type":"review","venue":"Oncogene","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":559,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; McGill University; McGill University Health Centre","funders":"","keywords":"Biology; Druggability; Melanoma; V600E; Cancer research; Mutation; Mutant; MAPK/ERK pathway; Cancer; Kinase; Colorectal cancer; Targeted therapy; Genetics; Gene","authors":[{"name":"Matthew Dankner","is_ca":true},{"name":"April A. N. Rose","is_ca":true},{"name":"Shivshankari Rajkumar","is_ca":true},{"name":"Peter M. Siegel","is_ca":true},{"name":"Ian R. Watson","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1142483572554173,"gpt":0.3914304546005842,"spread":0.277182097345167,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000767341,0.0008462463,0.001219208,0.001506258,0.0002239275,0.001038449,0.0009705423,0.001096009,0.002337048],"category_scores_gemma":[0.0008966416,0.0002471867,0.0004791616,0.001074448,0.0006381244,0.001273557,0.000654896,0.002466442,0.001208854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007883271,"about_ca_system_score_gemma":0.001014979,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007493715,"about_ca_topic_score_gemma":0.001963578,"domain_scores_codex":[0.9998071,0.00002889754,0.00002057563,0.00003985013,0.00007447023,0.00002912422],"domain_scores_gemma":[0.9997229,0.0001227805,0.00003347423,0.00001065134,0.00008333406,0.00002691438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001156835,0.00008004832,0.0003293158,0.006943098,0.00007711714,0.0002624729,0.00004308365,0.0005045114,0.004764744,0.005681898,0.03746106,0.9437371],"study_design_scores_gemma":[0.00003045602,0.0001157257,0.0006295619,0.001632136,0.0001720285,0.001531679,0.00005408587,0.0002695005,0.002479195,0.004457847,0.9886008,0.0000269265],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002359088,0.9971885,0.0006075531,0.0006411189,0.0003009919,0.000006489549,0.00003022562,0.00001878256,0.0009703959],"genre_scores_gemma":[0.002180228,0.9953062,0.0007047288,0.0005355757,0.0003003002,0.00001037454,0.00006775542,0.000003848323,0.0008910543],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002337048,"threshold_uncertainty_score":0.007818162,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4211123988","doi":"10.1016/s0140-6736(13)60802-8","title":"Cutaneous melanoma","year":2013,"lang":"en","type":"review","venue":"The Lancet","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":532,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Melanoma; Medicine; Immunotherapy; Oncology; Targeted therapy; Lymph node; Sentinel lymph node; Immunology; Cancer research; Internal medicine; Cancer","authors":[{"name":"Alexander M.M. Eggermont","is_ca":false},{"name":"Alan Spatz","is_ca":true},{"name":"Caroline Robert","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05328027353009913,"gpt":0.3025350624953358,"spread":0.2492547889652367,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002668145,0.0006914008,0.0008139997,0.001211713,0.0002476502,0.0008892539,0.0006013188,0.001074692,0.009285525],"category_scores_gemma":[0.0007577622,0.0002090465,0.0002921389,0.0008345661,0.0004525095,0.0009473247,0.000673913,0.00195092,0.005134457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005604252,"about_ca_system_score_gemma":0.0007637743,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001305949,"about_ca_topic_score_gemma":0.00386145,"domain_scores_codex":[0.9998821,0.00001731241,0.00001104578,0.0000244589,0.00004840575,0.00001663123],"domain_scores_gemma":[0.9998198,0.00006217448,0.00002599747,0.000009931346,0.00004914369,0.00003300922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006669269,0.0000265995,0.0001086675,0.003575847,0.0000256293,0.0002855643,0.00001582627,0.0001541411,0.0009209964,0.002646712,0.1693405,0.8228328],"study_design_scores_gemma":[0.00001904918,0.00002326222,0.0003168043,0.001427888,0.0000324346,0.001492017,0.00002225185,0.00004566977,0.0001591998,0.001119734,0.9953342,0.000007360725],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009765228,0.9910282,0.0002023672,0.001209799,0.002238167,0.000005599941,0.00003010061,0.00002331131,0.005164778],"genre_scores_gemma":[0.001584698,0.9873942,0.000262661,0.001883356,0.002038355,0.00000929024,0.00006985871,0.00000538445,0.006752171],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009285525,"threshold_uncertainty_score":0.0310632,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985309852","doi":"10.1038/nature08314","title":"A dimerization-dependent mechanism drives RAF catalytic activation","year":2009,"lang":"en","type":"article","venue":"Nature","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":498,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Institute for Research in Immunology and Cancer; Université de Montréal; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research","keywords":"MAPK/ERK pathway; Cell biology; Kinase; Receptor tyrosine kinase; Signal transduction; Tyrosine kinase; Chemistry; Phosphorylation; Biology","authors":[{"name":"Thanashan Rajakulendran","is_ca":true},{"name":"Malha Sahmi","is_ca":true},{"name":"Martin Lefrançois","is_ca":true},{"name":"Frank Sicheri","is_ca":true},{"name":"Marc Therrien","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0041429794295503,"gpt":0.2257316560204767,"spread":0.2215886765909263,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003069124,0.000247493,0.0001513548,0.0001632678,0.0005426345,0.0005361256,0.0003127682,0.0005647608,0.002615011],"category_scores_gemma":[0.0003043393,0.0002756045,0.0003019042,0.0001048823,0.0002906132,0.0006148273,0.000446479,0.001309585,0.001334445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005623212,"about_ca_system_score_gemma":0.0002353363,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002090391,"about_ca_topic_score_gemma":0.0004090273,"domain_scores_codex":[0.999762,0.00002690086,0.00001264154,0.00007396492,0.00005917046,0.00006537056],"domain_scores_gemma":[0.9998337,0.00002795071,0.0000227223,0.00004043131,0.00002043746,0.00005468916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008938211,0.00003584599,0.0002023902,0.00002113883,0.000004762263,0.0001256563,0.00001996436,0.00009669765,0.9937937,0.002970604,0.0004532822,0.002186623],"study_design_scores_gemma":[0.00003179008,0.00006205342,0.002860916,0.000004981414,0.000006437392,0.0008631243,0.00004772934,0.005516906,0.983381,0.001593099,0.005619738,0.00001225119],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9621217,0.001505478,0.02186604,0.001820298,0.0002824027,0.00006793143,0.0003522618,0.0006011795,0.01138278],"genre_scores_gemma":[0.9934525,0.0002265606,0.002292647,0.0001485241,0.00001965773,0.00001580016,0.0001840708,0.00001913231,0.003641073],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002615011,"threshold_uncertainty_score":0.008748055,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2594529508","doi":"10.1016/s1470-2045(17)30180-8","title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":491,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Dacarbazine; Medicine; Neuroblastoma RAS viral oncogene homolog; Hazard ratio; Melanoma; Internal medicine; Clinical endpoint; Population; Adverse effect; Oncology; Progression-free survival; Randomized controlled trial; Vemurafenib; Cancer; Confidence interval; Chemotherapy; Metastatic melanoma; Cancer research; Colorectal cancer","authors":[{"name":"Reinhard Dummer","is_ca":false},{"name":"Dirk Schadendorf","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false},{"name":"Ana Arance","is_ca":false},{"name":"Caroline Dutriaux","is_ca":false},{"name":"Anna Maria Di Giacomo","is_ca":false},{"name":"Piotr Rutkowski","is_ca":false},{"name":"Michele Del Vecchio","is_ca":false},{"name":"Ralf Gutzmer","is_ca":false},{"name":"Mario Mandalà","is_ca":false},{"name":"L. Thomas","is_ca":false},{"name":"Lev Demidov","is_ca":false},{"name":"Claus Garbe","is_ca":false},{"name":"David Hogg","is_ca":true},{"name":"Gabriella Liszkay","is_ca":false},{"name":"Paola Queirolo","is_ca":false},{"name":"Ernesto Wasserman","is_ca":false},{"name":"James Ford","is_ca":false},{"name":"Marine Weill","is_ca":false},{"name":"L. Andres Sirulnik","is_ca":false},{"name":"Valentine Jehl","is_ca":false},{"name":"Viviana Bozón","is_ca":false},{"name":"Georgina V. Long","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05756250214883237,"gpt":0.3665577832550817,"spread":0.3089952811062494,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001090091,0.001566223,0.002195093,0.0002578353,0.0003387462,0.001049009,0.0006212459,0.001164344,0.005276829],"category_scores_gemma":[0.001028892,0.0005082694,0.001701667,0.0003356217,0.0008511774,0.001179805,0.0004305122,0.00315426,0.0008562604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008750187,"about_ca_system_score_gemma":0.0006803627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001051057,"about_ca_topic_score_gemma":0.003370733,"domain_scores_codex":[0.9996853,0.000149741,0.00001296783,0.0000540892,0.00002190712,0.00007601962],"domain_scores_gemma":[0.9995885,0.00009496821,0.00008555307,0.00002969172,0.00002192239,0.0001793123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9669834,0.003071584,0.0007732742,0.0006593236,0.001165749,0.00005169411,0.0000794259,0.0007177944,0.003389788,0.0001677135,0.001290388,0.02164985],"study_design_scores_gemma":[0.942104,0.05258199,0.00240162,0.00005215643,0.0004144834,0.00006822674,0.00004682715,0.0004856678,0.0003248769,0.0003747268,0.001126075,0.00001922558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868499,0.006215176,0.0005420602,0.001236704,0.0006123555,0.001323702,0.0009218091,0.00008536401,0.002213067],"genre_scores_gemma":[0.9869363,0.003728971,0.0009371248,0.001289376,0.0002864495,0.001322463,0.001148756,0.00002876084,0.004321835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005276829,"threshold_uncertainty_score":0.01765275,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2029575024","doi":"10.1038/nm.2166","title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","year":2010,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":472,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"National Cancer Institute; National Institute on Drug Abuse; Canadian Institutes of Health Research; Weill Cornell Medical College; Howard Hughes Medical Institute","keywords":"Cancer research; Fusion gene; Prostate cancer; Chromoplexy; Cancer; Biology; Anaplastic lymphoma kinase; Oncogene; Oncogene Proteins; Melanoma; Viral Oncogene; Gene; Medicine; Lung cancer; Regulation of gene expression; Genetics; PCA3; Cell cycle; Internal medicine","authors":[{"name":"Nallasivam Palanisamy","is_ca":false},{"name":"Bushra Ateeq","is_ca":false},{"name":"Shanker Kalyana‐Sundaram","is_ca":false},{"name":"Dorothee Pflueger","is_ca":false},{"name":"Kalpana Ramnarayanan","is_ca":false},{"name":"Sunita Shankar","is_ca":false},{"name":"Bo Han","is_ca":false},{"name":"Qi Cao","is_ca":false},{"name":"Xuhong Cao","is_ca":false},{"name":"Khalid Suleman","is_ca":false},{"name":"Chandan Kumar‐Sinha","is_ca":false},{"name":"Saravana M. Dhanasekaran","is_ca":false},{"name":"Ying‐Bei Chen","is_ca":false},{"name":"Raquel Esgueva","is_ca":false},{"name":"Samprit Banerjee","is_ca":false},{"name":"Christopher J. Lafargue","is_ca":false},{"name":"Javed Siddiqui","is_ca":false},{"name":"Francesca Demichelis","is_ca":false},{"name":"Peter Möeller","is_ca":false},{"name":"Tarek A. Bismar","is_ca":true},{"name":"Rainer Kuefer","is_ca":false},{"name":"Douglas R. Fullen","is_ca":false},{"name":"Timothy M. Johnson","is_ca":false},{"name":"Joel K. Greenson","is_ca":false},{"name":"Thomas J. Giordano","is_ca":false},{"name":"Patrick Tan","is_ca":false},{"name":"Scott A. Tomlins","is_ca":false},{"name":"Sooryanarayana Varambally","is_ca":false},{"name":"Mark A. Rubin","is_ca":false},{"name":"Christopher A. Maher","is_ca":false},{"name":"Arul M. Chinnaiyan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005012724505159081,"gpt":0.2506074112941852,"spread":0.2455946867890262,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001291376,0.0001446196,0.00007991666,0.0005999389,0.0002276527,0.000296386,0.0001598721,0.0002404644,0.001397595],"category_scores_gemma":[0.0002048986,0.0001581876,0.0001085542,0.0002333115,0.0002581034,0.0002035535,0.0002190309,0.0003140685,0.0001908257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004036177,"about_ca_system_score_gemma":0.0002336312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001210195,"about_ca_topic_score_gemma":0.001437201,"domain_scores_codex":[0.9999294,0.00001970668,0.000004273134,0.000008693631,0.00001680515,0.00002108689],"domain_scores_gemma":[0.9999341,0.00001557193,0.00001785773,0.000008921445,0.00000692141,0.00001666369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001838923,0.00007558296,0.02177863,0.0001242035,0.00004407647,0.00468663,0.000185432,0.0009711719,0.9343547,0.01064469,0.0008251262,0.02447079],"study_design_scores_gemma":[0.0002407488,0.0007835983,0.4147752,0.00005238269,0.0002032842,0.0562164,0.001112293,0.003488312,0.4636798,0.0135319,0.045857,0.00005913374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867092,0.006228793,0.0007078758,0.0004426469,0.0000165112,0.000006893705,0.0001558622,0.00004282928,0.005689406],"genre_scores_gemma":[0.9970291,0.001586483,0.0001661933,0.00002531788,0.000008400787,0.000004256857,0.00006959414,0.00000514923,0.001105438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001397595,"threshold_uncertainty_score":0.004675448,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2102646127","doi":"10.1016/j.molcel.2005.10.022","title":"Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization","year":2005,"lang":"en","type":"article","venue":"Molecular Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":421,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Cancer Research UK; Cancer Research Institute","keywords":"Biology; Mutant; Genetics; Wild type; Cell biology; Mutation; Gene","authors":[{"name":"Mathew J. Garnett","is_ca":false},{"name":"Sareena Rana","is_ca":false},{"name":"Hugh Paterson","is_ca":false},{"name":"David Barford","is_ca":false},{"name":"Richard Marais","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007918534931107038,"gpt":0.2099768426774062,"spread":0.2020583077462992,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004052117,0.0004776278,0.0002276876,0.0003584209,0.00032176,0.0006631823,0.0003357518,0.0003758945,0.002410041],"category_scores_gemma":[0.0002473239,0.0003406019,0.0005673835,0.0002130234,0.0002243428,0.0005851926,0.0004509578,0.001097448,0.001120703],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003903085,"about_ca_system_score_gemma":0.0001618721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002591135,"about_ca_topic_score_gemma":0.0003981651,"domain_scores_codex":[0.9995624,0.00006677915,0.00003609945,0.00007869949,0.0001054844,0.0001505477],"domain_scores_gemma":[0.9998185,0.00004313032,0.00002575176,0.00003408354,0.0000298454,0.00004880818],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000116502,0.00004208914,0.0001610733,0.00002083902,0.000007418018,0.00003983928,0.00001245864,0.00001992351,0.9983165,0.0005851483,0.00007039974,0.0006078353],"study_design_scores_gemma":[0.00004290606,0.0001121832,0.00511124,0.000006619445,0.00002017594,0.0006515457,0.0000581095,0.001153842,0.9896702,0.0002295303,0.002933972,0.000009596159],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867631,0.002021907,0.005545235,0.0001785488,0.00008587923,0.00005432175,0.0003465099,0.0001363023,0.004868145],"genre_scores_gemma":[0.9906493,0.0007417398,0.002839806,0.00009754979,0.00002232893,0.00006820387,0.0007955254,0.00004368529,0.004741953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002410041,"threshold_uncertainty_score":0.008062422,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151507583","doi":"10.1634/theoncologist.12-4-426","title":"Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Clinical trial; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Drug; Toxicity; Safety profile; Phases of clinical research; Internal medicine; Medical physics; Adverse effect; Hepatocellular carcinoma","authors":[{"name":"Dirk Strumberg","is_ca":false},{"name":"Jeffrey W. Clark","is_ca":false},{"name":"Ahmad Awada","is_ca":false},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Heike Richly","is_ca":false},{"name":"Alain Hendlisz","is_ca":false},{"name":"Hal W. Hirte","is_ca":true},{"name":"Joseph P. Eder","is_ca":false},{"name":"Heinz‐Josef Lenz","is_ca":false},{"name":"Brian Schwartz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07306418962376841,"gpt":0.4061245175451803,"spread":0.3330603279214119,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003329077,0.0006980737,0.002896372,0.00193218,0.0002541079,0.001062597,0.001155016,0.0006359826,0.001087339],"category_scores_gemma":[0.004581099,0.0003545491,0.002193464,0.003031531,0.0004921373,0.001081118,0.0004078987,0.0008342118,0.0002975261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007506566,"about_ca_system_score_gemma":0.001566726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006792542,"about_ca_topic_score_gemma":0.001782806,"domain_scores_codex":[0.9989202,0.0003125216,0.000369933,0.0001342207,0.0002302259,0.00003291683],"domain_scores_gemma":[0.9960336,0.002241916,0.001026505,0.00007221165,0.0005094334,0.0001164512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.001252498,0.00009750547,0.001475196,0.1760388,0.002715233,0.0002687157,0.000233415,0.0005342602,0.004372681,0.0004966516,0.01043837,0.8020767],"study_design_scores_gemma":[0.002272693,0.007158772,0.0318829,0.1676176,0.04431845,0.006744361,0.0008203238,0.0009174586,0.006878522,0.002064865,0.7291472,0.0001768009],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001037387,0.9981744,0.0001741034,0.0001989796,0.0000398906,0.00002919867,0.00006912502,0.000009042171,0.000267875],"genre_scores_gemma":[0.00758832,0.9911885,0.0004534441,0.0003870451,0.00005733298,0.00005065822,0.000127815,0.000007009563,0.000139856],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003329077,"threshold_uncertainty_score":0.01760608,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2774483419","doi":"10.1158/2159-8290.cd-17-1119","title":"First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"Medicine; Adverse effect; Nausea; Neuroblastoma RAS viral oncogene homolog; Cohort; Response Evaluation Criteria in Solid Tumors; Tolerability; Internal medicine; Cancer; Pharmacokinetics; MEK inhibitor; Oncology; Gastroenterology; MAPK/ERK pathway; Pharmacology; Clinical trial; Phases of clinical research; Kinase; Colorectal cancer; KRAS","authors":[{"name":"Ryan J. Sullivan","is_ca":false},{"name":"Jeffrey R. Infante","is_ca":false},{"name":"Filip Jankú","is_ca":false},{"name":"Deborah Jean Lee Wong","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"Vicki L. Keedy","is_ca":false},{"name":"Manish R. Patel","is_ca":false},{"name":"Geoffrey I. Shapiro","is_ca":false},{"name":"James W. Mier","is_ca":false},{"name":"Anthony W. Tolcher","is_ca":false},{"name":"Andrea Wang‐Gillam","is_ca":false},{"name":"Mario Sznol","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false},{"name":"Elizabeth I. Buchbinder","is_ca":false},{"name":"Richard D. Carvajal","is_ca":false},{"name":"Anna M. Varghese","is_ca":false},{"name":"Mario E. Lacouture","is_ca":false},{"name":"Antoni Ribas","is_ca":false},{"name":"Sapna P. Patel","is_ca":false},{"name":"Gary DeCrescenzo","is_ca":true},{"name":"Anna Groover","is_ca":true},{"name":"Saurabh Saha","is_ca":true},{"name":"Mary Varterasian","is_ca":true},{"name":"Dean J. Welsch","is_ca":true},{"name":"David M. Hyman","is_ca":false},{"name":"Bob T. Li","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01034731323142016,"gpt":0.2735128579624377,"spread":0.2631655447310176,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001666246,0.0008991328,0.00112741,0.0002005308,0.0002682318,0.0006652549,0.0004721,0.0005014639,0.001310685],"category_scores_gemma":[0.0005273176,0.0002767356,0.001117932,0.0002656413,0.0004309842,0.0005333196,0.0002017389,0.002157013,0.0003887187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008626361,"about_ca_system_score_gemma":0.0008658,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008230916,"about_ca_topic_score_gemma":0.001939519,"domain_scores_codex":[0.9996195,0.0001622948,0.00002541927,0.00005493962,0.00005588095,0.00008202516],"domain_scores_gemma":[0.9996344,0.00006049642,0.00007333923,0.00003800579,0.00003573638,0.0001580533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2447366,0.08737255,0.03063749,0.00100469,0.002437976,0.0006830447,0.0008569576,0.008679187,0.2647606,0.0003688026,0.008877063,0.3495851],"study_design_scores_gemma":[0.2620578,0.5740362,0.1096443,0.00008631465,0.001564805,0.001756804,0.0001783741,0.006860142,0.035298,0.0003445342,0.008083727,0.0000890262],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968455,0.001172417,0.0003510807,0.0002038695,0.00002609394,0.0003490873,0.0003694515,0.00005174294,0.0006305982],"genre_scores_gemma":[0.9961303,0.0007493975,0.0009458842,0.0002806802,0.00003747377,0.0001794007,0.001072057,0.00001941327,0.0005852729],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001666246,"threshold_uncertainty_score":0.00881207,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1977852460","doi":"10.1073/pnas.0905139106","title":"Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival","year":2009,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":381,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; York University; Emerald Foundation; National Cancer Institute; National Science Foundation; National Institutes of Health; Cancer Research Institute","keywords":"Melanoma; Immune system; Tumor-infiltrating lymphocytes; Gene expression profiling; Mitotic index; Oncology; Metastasis; Survival analysis; Medicine; Cancer research; Immunology; Internal medicine; Biology; Gene expression; Cancer; Immunotherapy; Gene; Mitosis","authors":[{"name":"Dusan Bogunovic","is_ca":false},{"name":"David O’Neill","is_ca":false},{"name":"Ilana Belitskaya‐Lévy","is_ca":false},{"name":"Vladimir Vacic","is_ca":false},{"name":"Yi-Lo Yu","is_ca":false},{"name":"Sylvia Adams","is_ca":false},{"name":"Farbod Darvishian","is_ca":false},{"name":"Russell S. Berman","is_ca":false},{"name":"Richard L. Shapiro","is_ca":false},{"name":"Anna C. Pavlick","is_ca":false},{"name":"Stefano Lonardi","is_ca":false},{"name":"Jiří Zavadil","is_ca":false},{"name":"Iman Osman","is_ca":false},{"name":"Nina Bhardwaj","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0371327176768018,"gpt":0.3280444458010932,"spread":0.2909117281242914,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004930792,0.0002645376,0.0002728644,0.0006383963,0.0001377357,0.0003733659,0.00009165756,0.0002463604,0.0008794335],"category_scores_gemma":[0.0008936678,0.00009189262,0.0001880766,0.0003074392,0.0001467265,0.0001907133,0.0002167909,0.0003284859,0.0002956852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001234485,"about_ca_system_score_gemma":0.0001244283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003919243,"about_ca_topic_score_gemma":0.001188169,"domain_scores_codex":[0.9998772,0.0000447441,0.00001062604,0.00002079193,0.00002736694,0.00001921601],"domain_scores_gemma":[0.9996389,0.00009546436,0.0001001006,0.00001887726,0.00003851423,0.000108096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005708722,0.00004187336,0.9783981,0.00001548136,0.00003388529,0.00005454825,0.00002256179,0.0003281778,0.009076354,0.0000195596,0.0001288624,0.01130983],"study_design_scores_gemma":[0.000008148329,0.0001890885,0.9956658,0.000006447592,0.00004382874,0.000232533,0.00003830186,0.001853051,0.001545896,0.00006587472,0.0003469333,0.000004071529],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980364,0.0006440104,0.0004263251,0.00005806379,0.000007607637,0.00001009822,0.0001288606,0.00001159067,0.0006771202],"genre_scores_gemma":[0.9989418,0.0001770144,0.0004505493,0.00001685126,0.00001436048,0.000005939389,0.0001689022,0.000001827819,0.0002226553],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008794335,"threshold_uncertainty_score":0.002942026,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2064854415","doi":"10.1042/bj20110289","title":"Regulation and function of the RSK family of protein kinases","year":2011,"lang":"en","type":"review","venue":"Biochemical Journal","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":376,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Biology; Gene isoform; Kinase; Effector; Cell biology; Ribosomal s6 kinase; Caenorhabditis elegans; Function (biology); Signal transduction; MAPK/ERK pathway; SH3 domain; Genetics; Receptor tyrosine kinase; Gene; PI3K/AKT/mTOR pathway; P70-S6 Kinase 1","authors":[{"name":"Yves Roméo","is_ca":true},{"name":"Xiaocui Zhang","is_ca":true},{"name":"Philippe P. Roux","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0339763056822595,"gpt":0.2545984915611993,"spread":0.2206221858789398,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000353968,0.0007551461,0.0007489288,0.001055792,0.0001929166,0.0006982699,0.0006069289,0.0005708614,0.001008432],"category_scores_gemma":[0.0002793776,0.0002468675,0.0003050609,0.0008762472,0.0004925553,0.0008450393,0.0004503742,0.001093096,0.001685405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008020878,"about_ca_system_score_gemma":0.0005664944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004839743,"about_ca_topic_score_gemma":0.000653477,"domain_scores_codex":[0.9998292,0.00002336381,0.00002261837,0.00004024761,0.00006235087,0.00002216613],"domain_scores_gemma":[0.9999138,0.00002496318,0.00001944364,0.000004799722,0.00002416551,0.00001275168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002604464,0.00006746153,0.0007287952,0.009029737,0.0001381827,0.0007724044,0.0001217551,0.001396287,0.05280706,0.009249527,0.01251692,0.9129114],"study_design_scores_gemma":[0.00003587555,0.0000966206,0.003623055,0.0006333661,0.00008298065,0.003746202,0.00005909403,0.000359024,0.01916554,0.003362842,0.9688035,0.00003186978],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001816052,0.995355,0.0004964383,0.0002114385,0.0001027846,0.000004969157,0.00003042535,0.00001358798,0.001969378],"genre_scores_gemma":[0.00929012,0.988077,0.0005600621,0.0001115266,0.0001235764,0.00001164469,0.00007726771,0.000003376689,0.001745312],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001055792,"threshold_uncertainty_score":0.005819559,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2038264590","doi":"10.1158/2159-8290.cd-12-0386","title":"Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma","year":2012,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":373,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK; Wellcome Trust","keywords":"Vemurafenib; Dasatinib; Cancer research; Src family kinase; Melanoma; Tyrosine kinase; EGFR inhibitors; Metastasis; Epidermal growth factor receptor; Gefitinib; Medicine; Signal transduction; Kinase; Proto-oncogene tyrosine-protein kinase Src; Biology; Cancer; Oncogene; Internal medicine; Cell cycle; Cell biology","authors":[{"name":"María Romina Girotti","is_ca":true},{"name":"Malin Pedersen","is_ca":true},{"name":"Berta Sanchez‐Laorden","is_ca":true},{"name":"Amaya Virós","is_ca":true},{"name":"Samra Turajlic","is_ca":true},{"name":"Dan Niculescu‐Duvaz","is_ca":true},{"name":"Alfonso Zambon","is_ca":true},{"name":"John Sinclair","is_ca":true},{"name":"Andrew Hayes","is_ca":true},{"name":"Martin Gore","is_ca":true},{"name":"Paul Lorigan","is_ca":true},{"name":"Caroline J. Springer","is_ca":true},{"name":"James Larkin","is_ca":true},{"name":"Claus Jørgensen","is_ca":true},{"name":"Richard Marais","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02031716774709106,"gpt":0.2606265288370754,"spread":0.2403093610899843,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001416327,0.0003083551,0.0003192182,0.00017114,0.0001242403,0.0002268499,0.0002314895,0.0002601822,0.001309455],"category_scores_gemma":[0.00007853212,0.0000939142,0.0003435847,0.0001047215,0.0001256357,0.0001167841,0.0001344471,0.0004947482,0.0003916576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002102823,"about_ca_system_score_gemma":0.0001835464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004046576,"about_ca_topic_score_gemma":0.0007895913,"domain_scores_codex":[0.9999006,0.0000114541,0.0000107488,0.00001411772,0.0000328193,0.00003033029],"domain_scores_gemma":[0.9999553,0.000008044199,0.00001157275,0.000007441633,0.000007153677,0.00001049758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001371575,0.000112647,0.0003104896,0.00006629644,0.0000100454,0.0000719567,0.00001130162,0.0001593697,0.9920267,0.0001089926,0.0001154159,0.006869579],"study_design_scores_gemma":[0.00009007537,0.002171323,0.003855917,0.000008117049,0.00003162272,0.0009807221,0.00001526083,0.001084242,0.985254,0.00004131379,0.006461563,0.000005842707],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904108,0.004181257,0.002284244,0.0001626924,0.00007424704,0.00009887524,0.0003506349,0.0001442873,0.002292963],"genre_scores_gemma":[0.9935039,0.001913088,0.002044173,0.00005393591,0.00001582323,0.00004530236,0.0005311162,0.000021003,0.001871793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001309455,"threshold_uncertainty_score":0.004380584,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2171367970","doi":"10.1200/jco.2012.44.7888","title":"Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":363,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California, Los Angeles; Peter MacCallum Cancer Centre; Plexxikon; Vanderbilt University; Moffitt Cancer Center; Genentech; University of Pittsburgh; F. Hoffmann-La Roche; Vanderbilt-Ingram Cancer Center; York University; University of Pennsylvania; Massachusetts General Hospital; GlaxoSmithKline","keywords":"Vemurafenib; Medicine; Neuroblastoma RAS viral oncogene homolog; MAPK/ERK pathway; Cancer research; Melanoma; Kinase; Phosphorylation; Internal medicine; Cancer; Metastatic melanoma; KRAS; Biology; Colorectal cancer; Cell biology","authors":[{"name":"Kerstin Trunzer","is_ca":false},{"name":"Anna C. Pavlick","is_ca":false},{"name":"Lynn M. Schuchter","is_ca":false},{"name":"René González","is_ca":false},{"name":"Grant A. McArthur","is_ca":false},{"name":"Thomas E. Hutson","is_ca":false},{"name":"Stergios J. Moschos","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false},{"name":"Kevin B. Kim","is_ca":false},{"name":"Jeffrey S. Weber","is_ca":false},{"name":"Peter Hersey","is_ca":false},{"name":"Georgina V. Long","is_ca":false},{"name":"Donald P. Lawrence","is_ca":false},{"name":"Patrick A. Ott","is_ca":false},{"name":"Ravi K. Amaravadi","is_ca":false},{"name":"Karl D. Lewis","is_ca":false},{"name":"Igor Puzanov","is_ca":false},{"name":"Roger S. Lo","is_ca":false},{"name":"Astrid Koehler","is_ca":false},{"name":"Mark Kockx","is_ca":false},{"name":"Olivia Spleiss","is_ca":false},{"name":"Annette Schell-Steven","is_ca":false},{"name":"Houston Gilbert","is_ca":false},{"name":"Louise Cockey","is_ca":false},{"name":"Gideon Bollag","is_ca":false},{"name":"Richard J. Lee","is_ca":false},{"name":"Andrew K. Joe","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"Antoni Ribas","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01935879750345848,"gpt":0.3406378477840598,"spread":0.3212790502806013,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004204425,0.0002516537,0.0005878737,0.0002424533,0.0001729049,0.0002897028,0.000137194,0.0003287281,0.0006452168],"category_scores_gemma":[0.001868151,0.0001176593,0.0002606217,0.0002138072,0.0001560508,0.0002424812,0.0001264822,0.0003782055,0.0001255222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002794149,"about_ca_system_score_gemma":0.0001480309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002396402,"about_ca_topic_score_gemma":0.0004256183,"domain_scores_codex":[0.9996547,0.0001291819,0.00002898106,0.00006413867,0.00008335818,0.00003961222],"domain_scores_gemma":[0.9993561,0.0002134919,0.0002351841,0.00002272145,0.00004871493,0.000123857],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01013718,0.0004748961,0.8759732,0.0001778842,0.0004000119,0.001288667,0.0001553933,0.001452187,0.03444675,0.0001532183,0.0006605756,0.07467996],"study_design_scores_gemma":[0.00045756,0.006343929,0.9808958,0.00001881138,0.0002059504,0.00446924,0.00006877106,0.002191117,0.003583786,0.0002216778,0.001525202,0.00001815708],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996548,0.002211308,0.0002357321,0.0001518198,0.000007196614,0.00002278758,0.0001114526,0.00001317439,0.0006984993],"genre_scores_gemma":[0.9994136,0.0001755903,0.0001200131,0.00006155516,0.00002193974,0.00001189772,0.00009850605,0.000001883022,0.00009512289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0006452168,"threshold_uncertainty_score":0.002223492,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130044807","doi":"10.1038/sj.embor.embor939","title":"An essential function of the mitogen‐activated protein kinase Erk2 in mouse trophoblast development","year":2003,"lang":"en","type":"article","venue":"EMBO Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":359,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Centre National de la Recherche Scientifique; Cancer Research Society","keywords":"Trophoblast; Cell biology; Biology; MAPK/ERK pathway; Protein kinase A; Kinase; Embryonic stem cell; Embryogenesis; Embryo; Cell growth; Placenta; Fetus; Genetics; Gene","authors":[{"name":"Marc K. Saba-El-Leil","is_ca":true},{"name":"Francis Vella","is_ca":false},{"name":"Bertrand Vernay","is_ca":false},{"name":"Laure Voisin","is_ca":true},{"name":"Lan Chen","is_ca":false},{"name":"Nathalie Labrecque","is_ca":false},{"name":"Siew‐Lan Ang","is_ca":false},{"name":"Sylvain Meloche","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006149139100158751,"gpt":0.2061387202618671,"spread":0.1999895811617083,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002036484,0.0004084086,0.0001264772,0.0003035378,0.0002540048,0.0003660763,0.0002150685,0.000271211,0.001458528],"category_scores_gemma":[0.0001844694,0.0002783535,0.0002005164,0.0001148962,0.000246602,0.0003213499,0.0003397072,0.0005182331,0.0005219695],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003914855,"about_ca_system_score_gemma":0.0003094424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004607082,"about_ca_topic_score_gemma":0.0007600044,"domain_scores_codex":[0.9998895,0.00001975817,0.0000107889,0.00002136677,0.00002897499,0.00002960796],"domain_scores_gemma":[0.9998424,0.00002725581,0.00003182179,0.00002914703,0.00001970816,0.00004973359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001729326,0.000006044934,0.0002111209,0.00002821387,0.000002481934,0.0002045737,0.00001204143,0.00004770328,0.9976518,0.0006745519,0.00005548072,0.0009330987],"study_design_scores_gemma":[0.00001657818,0.00004991642,0.004637001,0.000006402733,0.00001170862,0.001093787,0.00002529913,0.0004612127,0.9893647,0.0002727844,0.004057215,0.000003369877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805154,0.004298249,0.007138906,0.0003250919,0.00006528936,0.00001970855,0.0006347291,0.0001826192,0.006820025],"genre_scores_gemma":[0.9916053,0.0008434553,0.002272834,0.00003804988,0.000009249402,0.00001791471,0.0004302007,0.00003307089,0.004749864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001458528,"threshold_uncertainty_score":0.004879236,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3034783173","doi":"10.1016/j.trecan.2020.05.009","title":"Clinical Development of BRAF plus MEK Inhibitor Combinations","year":2020,"lang":"en","type":"review","venue":"Trends in cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":352,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Daiichi Sankyo Company; Bristol-Myers Squibb Canada; Genentech; European Society for Medical Oncology; Exelixis; Prometheus; Roche; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; American Society of Clinical Oncology; AstraZeneca; Novartis; Spectrum Pharmaceuticals; Amgen; GlaxoSmithKline","keywords":"MEK inhibitor; Cancer research; Chemistry; Pharmacology; Medicine; MAPK/ERK pathway; Phosphorylation; Biochemistry","authors":[{"name":"Vivek Subbiah","is_ca":false},{"name":"Christina S. Baik","is_ca":false},{"name":"John M. Kirkwood","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1354341508561493,"gpt":0.4400165371099267,"spread":0.3045823862537773,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008348332,0.001057181,0.001723418,0.001000337,0.0001845437,0.001119179,0.001221464,0.001089105,0.005557346],"category_scores_gemma":[0.001004343,0.0002806069,0.0007831003,0.0007744572,0.0003897588,0.0009122512,0.0005068369,0.003434797,0.001816442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005553436,"about_ca_system_score_gemma":0.00069455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006651468,"about_ca_topic_score_gemma":0.002640109,"domain_scores_codex":[0.9998004,0.00004595229,0.00002252757,0.00004347075,0.00005934918,0.00002833805],"domain_scores_gemma":[0.999724,0.0001279432,0.00004539873,0.000008222833,0.00005333548,0.0000410758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004566463,0.0001988723,0.0001543537,0.00454149,0.0001229845,0.0001740905,0.00002429486,0.0005220821,0.001649535,0.001645758,0.02780221,0.9627076],"study_design_scores_gemma":[0.001315017,0.001337375,0.001898661,0.004007119,0.0004853161,0.001713379,0.0000515519,0.0005276144,0.00148041,0.00288174,0.9842595,0.00004230373],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006459283,0.9947895,0.000502563,0.0007363305,0.0004541693,0.00003248252,0.00006046466,0.00002650767,0.00275207],"genre_scores_gemma":[0.006890493,0.9859489,0.001065717,0.00206425,0.0005611489,0.00007525422,0.0002420707,0.00001180743,0.003140415],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005557346,"threshold_uncertainty_score":0.01859123,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948884915","doi":"10.1038/s41591-019-0476-5","title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":326,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health; Nature","keywords":"Medicine; Dabrafenib; Melanoma; Trametinib; Pembrolizumab; MEK inhibitor; Immunotherapy; Discontinuation; Blockade; Internal medicine; Oncology; Adverse effect; Combination therapy; Targeted therapy; MAPK/ERK pathway; Vemurafenib; Immunology; Pharmacology; Cancer research; Cancer; Kinase; Metastatic melanoma; Biology; Receptor","authors":[{"name":"Antoni Ribas","is_ca":false},{"name":"Donald P. Lawrence","is_ca":false},{"name":"Victoria Atkinson","is_ca":false},{"name":"Sachin Agarwal","is_ca":false},{"name":"Wilson H. Miller","is_ca":true},{"name":"Matteo S. Carlino","is_ca":false},{"name":"Rosalie Fisher","is_ca":false},{"name":"Georgina V. Long","is_ca":false},{"name":"F. Stephen Hodi","is_ca":false},{"name":"Jennifer Tsoi","is_ca":false},{"name":"Catherine S. Grasso","is_ca":false},{"name":"Bijoyesh Mookerjee","is_ca":false},{"name":"Qing Zhao","is_ca":false},{"name":"Razi Ghori","is_ca":false},{"name":"Blanca Homet Moreno","is_ca":false},{"name":"Nageatte Ibrahim","is_ca":false},{"name":"Omid Hamid","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.002431315230869503,"gpt":0.2083139023884205,"spread":0.205882587157551,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001745735,0.000266005,0.0004259272,0.0002043147,0.0001661311,0.000328238,0.0002468734,0.0002203694,0.001128733],"category_scores_gemma":[0.00009381028,0.0001237611,0.0003084545,0.0001541238,0.0001375222,0.0002897495,0.0001783696,0.0008703251,0.0002221457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003492339,"about_ca_system_score_gemma":0.0003701439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005120226,"about_ca_topic_score_gemma":0.001974318,"domain_scores_codex":[0.9999104,0.00001630541,0.000005178309,0.0000132649,0.00002009404,0.00003479901],"domain_scores_gemma":[0.9999729,0.000004616799,0.000004336064,0.000003147795,0.00000246358,0.0000125152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02975356,0.008071122,0.003175928,0.0005255238,0.0004770741,0.0004745892,0.0001012772,0.00655163,0.5951959,0.001491532,0.004314034,0.3498678],"study_design_scores_gemma":[0.01663611,0.1690785,0.07269099,0.000168673,0.001823874,0.004379998,0.0002762194,0.03160855,0.6410629,0.003051793,0.05907734,0.0001450314],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873733,0.007237405,0.0007034624,0.0003749662,0.0001929236,0.00007040163,0.0001135862,0.00007958963,0.003854393],"genre_scores_gemma":[0.9963798,0.001465832,0.0004916603,0.00006988951,0.00003625384,0.00003688768,0.00008095473,0.000006140328,0.001432556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001128733,"threshold_uncertainty_score":0.003776014,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948740360","doi":"10.1038/s41591-019-0448-9","title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":323,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme","keywords":"Dabrafenib; Trametinib; Pembrolizumab; Melanoma; Medicine; Mutant; Cancer research; Oncology; Internal medicine; Vemurafenib; Biology; Immunotherapy; Metastatic melanoma; Genetics; MAPK/ERK pathway; Cancer; Phosphorylation; Gene","authors":[{"name":"Paolo A. Ascierto","is_ca":false},{"name":"Pier Francesco Ferrucci","is_ca":false},{"name":"Rosalie Fisher","is_ca":false},{"name":"Michele Del Vecchio","is_ca":false},{"name":"Victoria Atkinson","is_ca":false},{"name":"Henrik Schmidt","is_ca":false},{"name":"Jacob Schachter","is_ca":false},{"name":"Paola Queirolo","is_ca":false},{"name":"Georgina V. Long","is_ca":false},{"name":"Anna Maria Di Giacomo","is_ca":false},{"name":"Inge Marie Svane","is_ca":false},{"name":"Michal Lotem","is_ca":false},{"name":"Gil Bar‐Sela","is_ca":false},{"name":"Félix Couture","is_ca":true},{"name":"Bijoyesh Mookerjee","is_ca":false},{"name":"Razi Ghori","is_ca":false},{"name":"Nageatte Ibrahim","is_ca":false},{"name":"Blanca Homet Moreno","is_ca":false},{"name":"Antoni Ribas","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005862682673053842,"gpt":0.2530370359029938,"spread":0.24717435322994,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008483264,0.0006293497,0.002268863,0.0002968122,0.0002773699,0.0005206048,0.0004340798,0.0007718318,0.004805785],"category_scores_gemma":[0.0009898683,0.0003138249,0.0008639482,0.0003063511,0.0004194739,0.0008855728,0.0002245763,0.00155858,0.000397853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003910936,"about_ca_system_score_gemma":0.0007733362,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00107831,"about_ca_topic_score_gemma":0.002564909,"domain_scores_codex":[0.9996849,0.0001541951,0.00002113181,0.00003422863,0.00001695395,0.00008863019],"domain_scores_gemma":[0.9996232,0.0001287477,0.00004844799,0.0000223066,0.00001438312,0.0001627895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9436631,0.004062698,0.0004547462,0.0003710003,0.0003780657,0.0000886518,0.00004580595,0.0003841535,0.01186046,0.0001680375,0.0009705776,0.03755264],"study_design_scores_gemma":[0.4794901,0.4729005,0.02351624,0.0001736461,0.001918504,0.0004409207,0.0002840681,0.001721845,0.01089286,0.0009164371,0.007663972,0.00008084795],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840342,0.01173211,0.0001243403,0.0007040221,0.0006864867,0.0001287392,0.0004345088,0.00004652407,0.002109103],"genre_scores_gemma":[0.9912642,0.004671343,0.000235663,0.0002271954,0.0002802151,0.0001555547,0.0002759781,0.00000655437,0.002883324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004805785,"threshold_uncertainty_score":0.01607692,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089686819","doi":"10.1016/j.celrep.2014.02.045","title":"Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3","year":2014,"lang":"en","type":"article","venue":"Cell Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":316,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero dell’Istruzione, dell’Università e della Ricerca; Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"KRAS; ERBB3; Kinome; Downregulation and upregulation; Cancer research; Receptor tyrosine kinase; Mutant; Cetuximab; ErbB; MEK inhibitor; Kinase; Colorectal cancer; Biology; Cancer; MAPK/ERK pathway; Signal transduction; Medicine; Cell biology; Internal medicine; Gene; Biochemistry","authors":[{"name":"Chong Sun","is_ca":false},{"name":"Sebastijan Hobor","is_ca":false},{"name":"Andrea Bertotti","is_ca":false},{"name":"Davide Zecchin","is_ca":false},{"name":"Sidong Huang","is_ca":true},{"name":"Francesco Galimi","is_ca":false},{"name":"Francesca Cottino","is_ca":false},{"name":"Anirudh Prahallad","is_ca":false},{"name":"Wipawadee Grernrum","is_ca":false},{"name":"Anna Tzani","is_ca":false},{"name":"Andreas Schlicker","is_ca":false},{"name":"Lodewyk F.A. Wessels","is_ca":false},{"name":"Egbert F. Smit","is_ca":false},{"name":"Erik Thunnissen","is_ca":false},{"name":"Pasi Halonen","is_ca":false},{"name":"Cor Lieftink","is_ca":false},{"name":"Roderick L. Beijersbergen","is_ca":false},{"name":"Federica Di Nicolantonio","is_ca":false},{"name":"Alberto Bardelli","is_ca":false},{"name":"Livio Trusolino","is_ca":false},{"name":"René Bernards","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008725670807022873,"gpt":0.2299171364603361,"spread":0.2211914656533132,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008346912,0.000173961,0.0001531053,0.0001485356,0.00009882838,0.0002249468,0.00009439931,0.0001215992,0.0009552267],"category_scores_gemma":[0.00007456654,0.00009360279,0.0001535551,0.0001110281,0.0001131195,0.00009236369,0.0001199644,0.0003806594,0.0002485334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002104056,"about_ca_system_score_gemma":0.0001676243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004610151,"about_ca_topic_score_gemma":0.001368574,"domain_scores_codex":[0.999925,0.00001126336,0.000006676551,0.000009217956,0.00002578633,0.00002201436],"domain_scores_gemma":[0.9999553,0.000007924925,0.00001150072,0.000007060503,0.000005093906,0.00001309555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00005246155,0.00001582164,0.0004717023,0.00001453202,0.000003765639,0.00003420914,0.000005345441,0.000136663,0.9978552,0.0001014878,0.00003881309,0.001269832],"study_design_scores_gemma":[0.00001143642,0.0003397618,0.007152156,0.000002899232,0.00001092601,0.0005000993,0.00001697171,0.0009707881,0.9896753,0.00005677543,0.001259918,0.000002828923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972332,0.0006273661,0.0007710301,0.00006554249,0.000005450403,0.000008974018,0.0001411734,0.00004734673,0.001099952],"genre_scores_gemma":[0.998261,0.0003237349,0.0004666151,0.0000154904,0.000001915386,0.000007658396,0.0001191831,0.00000677666,0.0007975214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009552267,"threshold_uncertainty_score":0.003195524,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2075925391","doi":"10.1016/j.cell.2014.11.053","title":"Pathological Axonal Death through a MAPK Cascade that Triggers a Local Energy Deficit","year":2015,"lang":"en","type":"article","venue":"Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":306,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; University of Ottawa","funders":"National Institute of Neurological Disorders and Stroke","keywords":"MAPK/ERK pathway; Biology; Cell biology; Neuroscience; Axon; Protein kinase A; Signal transduction; Programmed cell death; Autophagy; Kinase; Apoptosis; Genetics","authors":[{"name":"Jing Yang","is_ca":false},{"name":"Zhuhao Wu","is_ca":false},{"name":"Nicolas Renier","is_ca":false},{"name":"David Simon","is_ca":false},{"name":"Kunihiro Uryu","is_ca":false},{"name":"David S. Park","is_ca":true},{"name":"Peter A. Greer","is_ca":true},{"name":"Cathy Tournier","is_ca":false},{"name":"Roger J. Davis","is_ca":false},{"name":"Marc Tessier‐Lavigne","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04483218265073828,"gpt":0.2411561921684091,"spread":0.1963240095176708,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001252593,0.0003901943,0.0001546951,0.0002635392,0.0002884076,0.0002901683,0.0002164976,0.0004020088,0.001682891],"category_scores_gemma":[0.00007891294,0.0001199192,0.0002575768,0.0001420759,0.0002361986,0.0003836952,0.0002858502,0.0005962648,0.0002494377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003662343,"about_ca_system_score_gemma":0.0002121081,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004763851,"about_ca_topic_score_gemma":0.0007451189,"domain_scores_codex":[0.9999305,0.00001121679,0.00000491179,0.00001251407,0.0000151097,0.00002572002],"domain_scores_gemma":[0.9999591,0.000004475939,0.00001114795,0.000007016416,0.000006173086,0.00001194497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003766065,0.00004126409,0.0005135529,0.0000599413,0.00001288603,0.0009489817,0.00002222145,0.0001410288,0.9951009,0.00105678,0.0001339338,0.001591798],"study_design_scores_gemma":[0.00006561452,0.0005643613,0.01238981,0.00002539714,0.00004857284,0.003554424,0.0001765297,0.00181013,0.9766967,0.001789448,0.002866497,0.00001240199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897259,0.001818666,0.003852131,0.0004259766,0.00006263446,0.00003055286,0.0001730436,0.00009544313,0.003815636],"genre_scores_gemma":[0.9968678,0.0006010506,0.0007757788,0.00005687173,0.000007253919,0.00001846332,0.00005358127,0.000005941132,0.001613142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001682891,"threshold_uncertainty_score":0.005629778,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099259685","doi":"10.1093/annonc/mdi310","title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":301,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Bayer (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Toxicity; Adverse effect; Kinase; Internal medicine; Bay; Pharmacology; Refractory (planetary science); Tyrosine-kinase inhibitor; Cancer; Gastroenterology; Oncology","authors":[{"name":"Malcolm J. Moore","is_ca":false},{"name":"Holger W. Hirte","is_ca":true},{"name":"Lillian L. Siu","is_ca":false},{"name":"Amit M. Oza","is_ca":false},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Oana Petrenciuc","is_ca":true},{"name":"Frank Cihon","is_ca":false},{"name":"Chetan Lathia","is_ca":false},{"name":"Brian Schwartz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03243005053116366,"gpt":0.3398462573339467,"spread":0.307416206802783,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007216412,0.001346553,0.002069103,0.0003629276,0.0004466952,0.0008426796,0.000663846,0.0009903872,0.002893854],"category_scores_gemma":[0.0008352256,0.0006437227,0.001028204,0.0003989686,0.00101592,0.0008056667,0.0002252509,0.003881328,0.0007625729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009018059,"about_ca_system_score_gemma":0.001784212,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001354784,"about_ca_topic_score_gemma":0.002681493,"domain_scores_codex":[0.9997494,0.00009831294,0.000008405795,0.00004972716,0.00002393175,0.00007020917],"domain_scores_gemma":[0.999261,0.0001157159,0.0001473209,0.00006737437,0.00003300767,0.000375538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7513065,0.07048776,0.006813663,0.0003273947,0.0009629992,0.0003373265,0.0002748891,0.003967244,0.08132476,0.0004959251,0.003961244,0.07974026],"study_design_scores_gemma":[0.4222872,0.5510301,0.01449409,0.00001863869,0.0004278074,0.000450709,0.00006383799,0.002317866,0.005918814,0.0003763704,0.00257912,0.00003550657],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995596,0.0008768265,0.0005456453,0.0002938801,0.00008081156,0.0007811275,0.0005781588,0.00008269568,0.001164944],"genre_scores_gemma":[0.9927766,0.0009097505,0.001236535,0.0004529625,0.0001626886,0.001104665,0.001161704,0.0000378657,0.002157218],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002893854,"threshold_uncertainty_score":0.009680927,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973460380","doi":"10.1016/j.bbamcr.2006.11.001","title":"Atypical mitogen-activated protein kinases: Structure, regulation and functions","year":2006,"lang":"en","type":"review","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":299,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canada Research Chairs","keywords":"MAPK7; MAPKAPK2; Mitogen-activated protein kinase; MAPK14; Kinase; MAP kinase kinase kinase; MAP2K7; c-Raf; Biology; Cell biology; ASK1; Protein-Serine-Threonine Kinases; p38 mitogen-activated protein kinases; Mitogen-activated protein kinase kinase; MAPK/ERK pathway; Protein kinase A; Cyclin-dependent kinase 2","authors":[{"name":"Philippe Coulombe","is_ca":true},{"name":"Sylvain Meloche","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04603407875994522,"gpt":0.3393542111267232,"spread":0.293320132366778,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005855664,0.001296071,0.001597604,0.001613462,0.000336955,0.001117827,0.001398614,0.001076605,0.002110785],"category_scores_gemma":[0.0005221743,0.0004079358,0.0003170744,0.002706541,0.0006863317,0.001726475,0.000571742,0.002011119,0.002901347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000782212,"about_ca_system_score_gemma":0.0009632464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007330899,"about_ca_topic_score_gemma":0.001716021,"domain_scores_codex":[0.9998564,0.00001360565,0.0000209132,0.00003009692,0.00006103179,0.00001805236],"domain_scores_gemma":[0.999782,0.00007165864,0.00003922456,0.00001120828,0.00006337751,0.00003245463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001891024,0.00006832123,0.0001812519,0.00752364,0.00005159253,0.0003404311,0.00005277634,0.0003711997,0.007708003,0.002711317,0.02688731,0.9539152],"study_design_scores_gemma":[0.00003100822,0.00005307631,0.0007060202,0.0005515264,0.00007348521,0.001604381,0.00005306654,0.00008243426,0.001728645,0.001659788,0.9934391,0.0000174086],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000225196,0.9980878,0.0003534124,0.0001802075,0.0002965746,0.00000502477,0.00002576658,0.00001306093,0.000812932],"genre_scores_gemma":[0.001088516,0.9967266,0.0005178134,0.0001480909,0.0002950146,0.0000108891,0.00006587394,0.000001813572,0.001145278],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002110785,"threshold_uncertainty_score":0.007061243,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144708319","doi":"10.1016/j.ccr.2011.04.002","title":"c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":297,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Oncogene; MAPK/ERK pathway; Cancer research; Kinase; Biology; Concomitant; Anti-apoptotic Ras signalling cascade; Lung; Carcinoma; clone (Java method); Cell; Medicine; Cell biology; Internal medicine; Cell cycle; Gene; Genetics","authors":[{"name":"Rafael B. Blasco","is_ca":false},{"name":"Sarah Francoz","is_ca":false},{"name":"David Santamarı́a","is_ca":false},{"name":"Marta Cañamero","is_ca":false},{"name":"Pierre Dubus","is_ca":false},{"name":"Jean Charron","is_ca":true},{"name":"Manuela Baccarini","is_ca":false},{"name":"Mariano Barbacid","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02556869564990289,"gpt":0.2407732591841122,"spread":0.2152045635342093,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001548989,0.0002894359,0.0001587217,0.0005190893,0.0003709116,0.0003608368,0.0002642918,0.0002733448,0.001829599],"category_scores_gemma":[0.0002130293,0.0002764337,0.0002173603,0.0001435926,0.0002420532,0.0002470538,0.0002807343,0.0008062031,0.0008549861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005533184,"about_ca_system_score_gemma":0.0004251536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00157305,"about_ca_topic_score_gemma":0.002757624,"domain_scores_codex":[0.9997818,0.00003245178,0.00002664441,0.0000311765,0.00007893265,0.00004899171],"domain_scores_gemma":[0.9996923,0.00007211253,0.00005237555,0.00005116042,0.00003733255,0.00009483643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00006931376,0.00001932081,0.0001686894,0.000008153806,0.000001727463,0.0001097212,0.000006542433,0.00002895508,0.9989346,0.0001990886,0.00003726254,0.0004167088],"study_design_scores_gemma":[0.00001109599,0.00007513574,0.004704589,0.000002803119,0.000008192324,0.000835394,0.00002512464,0.001110949,0.9904906,0.00009643914,0.002636065,0.000003691295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930126,0.0008260848,0.002116111,0.0001615783,0.00002698143,0.00002197426,0.0004027183,0.0001131493,0.003318803],"genre_scores_gemma":[0.9944465,0.0003150243,0.001016148,0.00002507503,0.000004748425,0.00001480562,0.0004611714,0.00003247758,0.003683946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001829599,"threshold_uncertainty_score":0.006120622,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163563579","doi":"10.1016/s1470-2045(14)70051-8","title":"Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":292,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Vemurafenib; Rash; Adverse effect; Internal medicine; Nausea; Clinical endpoint; Population; Dacarbazine; Expanded access; Interim analysis; Dermatology; Surgery; Oncology; Gastroenterology; Clinical trial; Metastatic melanoma; Chemotherapy; Cancer","authors":[{"name":"James Larkin","is_ca":false},{"name":"Michele Del Vecchio","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false},{"name":"Ivana Krajsová","is_ca":false},{"name":"Jacob Schachter","is_ca":false},{"name":"Bart Neyns","is_ca":false},{"name":"Enrique Espinosa","is_ca":false},{"name":"Claus Garbe","is_ca":false},{"name":"Vanna Chiarion‐Sileni","is_ca":false},{"name":"Helen Gogas","is_ca":false},{"name":"Wilson H. Miller","is_ca":true},{"name":"Mario Mandalà","is_ca":false},{"name":"Geke A.P. Hospers","is_ca":false},{"name":"Ana Arance","is_ca":false},{"name":"Paola Queirolo","is_ca":false},{"name":"Axel Hauschild","is_ca":false},{"name":"Michael P. Brown","is_ca":false},{"name":"Lada Mitchell","is_ca":false},{"name":"L. Véronèse","is_ca":false},{"name":"Christian U. Blank","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03517410555670822,"gpt":0.3139019102081614,"spread":0.2787278046514532,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001647898,0.001212966,0.002135055,0.000232254,0.0002774341,0.00125904,0.0004963301,0.001195959,0.001833898],"category_scores_gemma":[0.002178786,0.000504809,0.002282771,0.0003805183,0.0007063817,0.001246019,0.0003342321,0.002149305,0.0004050506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007314818,"about_ca_system_score_gemma":0.0006434712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004036123,"about_ca_topic_score_gemma":0.0008681738,"domain_scores_codex":[0.9991993,0.0004043987,0.00004661435,0.0001457737,0.00009404312,0.0001098515],"domain_scores_gemma":[0.9986965,0.0004065158,0.0003798478,0.0001415596,0.00009365274,0.0002818249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.905978,0.005380731,0.01558142,0.001198772,0.005867776,0.0002744225,0.0001737041,0.001510097,0.01150466,0.0002380698,0.001662317,0.05063002],"study_design_scores_gemma":[0.6889001,0.2103227,0.08212624,0.0001717702,0.006042107,0.001004692,0.0002048554,0.002743351,0.002617821,0.0009312122,0.004794317,0.0001408334],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944658,0.003275065,0.0004562912,0.0002617521,0.00008114633,0.000212167,0.0005488306,0.00003220094,0.0006670152],"genre_scores_gemma":[0.996393,0.001218615,0.0003693493,0.0003720066,0.0001381241,0.0002062734,0.0006499981,0.0000139715,0.0006385967],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002135055,"threshold_uncertainty_score":0.008715034,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2079421845","doi":"10.1371/journal.pone.0029336","title":"Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":286,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; York University; U.S. Department of Veterans Affairs","keywords":"Tumor heterogeneity; Metastatic melanoma; Melanoma; Primary (astronomy); Primary tumor; Medicine; Cancer research; Oncology; Metastasis; Biology; Pathology; Internal medicine; Cancer","authors":[{"name":"Molly Yancovitz","is_ca":false},{"name":"Adam J. Litterman","is_ca":false},{"name":"Joanne Yoon","is_ca":false},{"name":"Elise Ng","is_ca":false},{"name":"Richard L. Shapiro","is_ca":false},{"name":"Russell S. Berman","is_ca":false},{"name":"Anna C. Pavlick","is_ca":false},{"name":"Farbod Darvishian","is_ca":false},{"name":"Paul J. Christos","is_ca":false},{"name":"Madhu Mazumdar","is_ca":false},{"name":"Iman Osman","is_ca":false},{"name":"David Polsky","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02978751268876376,"gpt":0.23192001735447,"spread":0.2021325046657062,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002506717,0.00009312328,0.0002077107,0.0004668285,0.0001451431,0.0002488737,0.00009254513,0.0001858347,0.0006930402],"category_scores_gemma":[0.0008512922,0.000154657,0.00009802188,0.0001484421,0.0002302783,0.0001221059,0.0001506687,0.0001740434,0.0001404732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001928962,"about_ca_system_score_gemma":0.00007071759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003822702,"about_ca_topic_score_gemma":0.0006758934,"domain_scores_codex":[0.9997763,0.00003983622,0.00002046755,0.00007040344,0.00005919135,0.0000336774],"domain_scores_gemma":[0.9996935,0.0001159976,0.00006923961,0.00003723509,0.00003368809,0.00005031877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0009624876,0.00008108981,0.3668577,0.00006041303,0.00005608278,0.001971008,0.000369539,0.0005575154,0.6110728,0.0001359886,0.00009756639,0.01777774],"study_design_scores_gemma":[0.00002692896,0.0006440039,0.9014163,0.000008666829,0.00006832909,0.01351513,0.0001975649,0.001713506,0.08104222,0.0003218549,0.001030798,0.00001464396],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99925,0.0002450777,0.000285968,0.000006573178,0.000001128569,0.00000616692,0.00002705799,0.000005886717,0.0001721342],"genre_scores_gemma":[0.999621,0.00004925421,0.0002205018,0.000005530187,0.000002397016,0.000004849056,0.00003698728,0.000002020493,0.00005744173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0006930402,"threshold_uncertainty_score":0.002318501,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2740393355","doi":"10.1093/annonc/mdx339","title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":258,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Confidence interval; Hazard ratio; Internal medicine; Metastatic melanoma; Progression-free survival; Melanoma; Gastroenterology; Oncology; Chemotherapy; Cancer; Cancer research","authors":[{"name":"Paul B. Chapman","is_ca":false},{"name":"Caroline Robert","is_ca":false},{"name":"James Larkin","is_ca":false},{"name":"John B.A.G. Haanen","is_ca":false},{"name":"Antoni Ribas","is_ca":false},{"name":"David Hogg","is_ca":true},{"name":"Omid Hamid","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false},{"name":"Alessandro Testori","is_ca":false},{"name":"Paul Lorigan","is_ca":false},{"name":"Reinhard Dummer","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"Keith T. Flaherty","is_ca":false},{"name":"Ilsung Chang","is_ca":false},{"name":"Samuel S. Coleman","is_ca":false},{"name":"Ivor Caro","is_ca":false},{"name":"Axel Hauschild","is_ca":false},{"name":"Grant A. McArthur","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04370504422132651,"gpt":0.3263825167606763,"spread":0.2826774725393497,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001280435,0.0009519703,0.00169728,0.0002026967,0.0002320003,0.00092976,0.0005298927,0.0007006317,0.001783828],"category_scores_gemma":[0.0009903872,0.000412796,0.002095418,0.0002326023,0.0004569187,0.0007880582,0.0003911702,0.001959415,0.0003488002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007712723,"about_ca_system_score_gemma":0.0005833199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008431884,"about_ca_topic_score_gemma":0.002371775,"domain_scores_codex":[0.9995809,0.0002138041,0.00002053037,0.00005671828,0.00004021648,0.00008779708],"domain_scores_gemma":[0.9996634,0.00008114579,0.00009732751,0.00003406669,0.00002062941,0.0001034616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8918924,0.003499961,0.009892793,0.001141225,0.005480258,0.0001506114,0.0001039049,0.003003365,0.009927466,0.0003547744,0.003273144,0.07128015],"study_design_scores_gemma":[0.8263823,0.0866906,0.06815103,0.0001443879,0.007291242,0.0003184315,0.0001553063,0.003055059,0.002354978,0.001051258,0.004313373,0.00009215372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906645,0.006595629,0.0002945755,0.0005552655,0.0001775321,0.000138329,0.0004468793,0.00004683572,0.001080567],"genre_scores_gemma":[0.9955441,0.001866854,0.0002753481,0.0004369141,0.0001317754,0.0001781053,0.0006354518,0.00001640662,0.0009150112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001783828,"threshold_uncertainty_score":0.006771684,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2078902726","doi":"10.1038/nchembio.1629","title":"A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics","year":2014,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":248,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Canadian Institutes of Health Research; Cancer Research UK; Wellcome Trust","keywords":"Binding site; Receptor–ligand kinetics; Kinase; Kinetics; Chemistry; Plasma protein binding; Biophysics; MAPK/ERK pathway; Pyrimidine; Biochemistry; Stereochemistry; Biology; Receptor","authors":[{"name":"A. Chaikuad","is_ca":false},{"name":"Eliana MC Tacconi","is_ca":false},{"name":"J. Zimmer","is_ca":false},{"name":"Yanke Liang","is_ca":false},{"name":"Nathanael S. Gray","is_ca":false},{"name":"Madalena Tarsounas","is_ca":false},{"name":"Stefan Knapp","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005112793602613707,"gpt":0.2249571127614532,"spread":0.2198443191588395,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004429353,0.0005262523,0.0006483961,0.0003685709,0.0005559347,0.0007250271,0.0009833673,0.0005955969,0.003994131],"category_scores_gemma":[0.0009140382,0.0006622573,0.0006832553,0.0002543113,0.0005020187,0.0007800166,0.0003659329,0.001547783,0.001298744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007147241,"about_ca_system_score_gemma":0.0003913512,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001415001,"about_ca_topic_score_gemma":0.001292199,"domain_scores_codex":[0.9996291,0.00004068688,0.00001921,0.000117223,0.0001030645,0.00009061996],"domain_scores_gemma":[0.9991266,0.0003126765,0.0002164292,0.0001026575,0.00009443521,0.0001472509],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005649026,0.00007772339,0.0004841432,0.0000667105,0.00003536622,0.000192434,0.0000362393,0.0007272781,0.9928999,0.001506196,0.0002602778,0.003148885],"study_design_scores_gemma":[0.0000693107,0.0001553263,0.004656488,0.000008055144,0.00004676238,0.0008294033,0.00002296693,0.01033564,0.9817145,0.0006791675,0.001436141,0.00004623415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9560705,0.0008207459,0.03744656,0.0003223155,0.0000843499,0.00006839167,0.0005021885,0.0005404867,0.004144389],"genre_scores_gemma":[0.9891048,0.0001986203,0.007930376,0.0001259688,0.00001383139,0.00005415268,0.0004685825,0.0001449759,0.00195859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003994131,"threshold_uncertainty_score":0.01336169,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1965097080","doi":"10.1158/1535-7163.mct-04-0297","title":"Raf kinase as a target for anticancer therapeutics","year":2005,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":247,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"MAPK/ERK pathway; Receptor tyrosine kinase; Kinase; Tyrosine kinase; Cancer research; Signal transduction; Biology; Medicine; Cell biology","authors":[{"name":"Srikala S. Sridhar","is_ca":true},{"name":"David W. Hedley","is_ca":true},{"name":"Lillian L. Siu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05591067051033215,"gpt":0.3620443422933081,"spread":0.3061336717829759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004086221,0.0007972847,0.001201162,0.0018327,0.0003140108,0.0007984849,0.0006603867,0.001259604,0.004600277],"category_scores_gemma":[0.0002416707,0.000309167,0.0004083297,0.001038961,0.0004518634,0.001157217,0.0005106917,0.002204577,0.004564985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008102807,"about_ca_system_score_gemma":0.0005276783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005228252,"about_ca_topic_score_gemma":0.001358371,"domain_scores_codex":[0.999849,0.00002326447,0.00001311496,0.00002860405,0.00006938945,0.00001661308],"domain_scores_gemma":[0.999913,0.00003211134,0.00001203317,0.000004886377,0.00002675534,0.00001126391],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001055632,0.000155805,0.0001526902,0.00678025,0.00006514633,0.000749514,0.0000807338,0.0008187987,0.01444434,0.01197362,0.04159804,0.9230754],"study_design_scores_gemma":[0.00003225938,0.0001034725,0.0003173159,0.0007546347,0.00003403379,0.00167106,0.00002397789,0.0001409547,0.001860008,0.002373693,0.992676,0.00001269117],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003678441,0.9930477,0.0004341239,0.0005790961,0.0003264497,0.00001251217,0.00002074588,0.00002085433,0.005190707],"genre_scores_gemma":[0.002584234,0.9908551,0.0006722364,0.0005736611,0.0002611825,0.00002424654,0.00004381238,0.000004314791,0.00498122],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004600277,"threshold_uncertainty_score":0.0153895,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137990944","doi":"10.1186/1756-8722-3-8","title":"From basic research to clinical development of MEK1/2 inhibitors for cancer therapy","year":2010,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":244,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Cancer research; Regulator; Cancer; Kinase; Receptor tyrosine kinase; MAPK/ERK pathway; Hematology; Tyrosine kinase; Signal transduction; Function (biology); Hyperactivation; Medicine; Biology; Internal medicine; Cell biology; Gene; Biochemistry","authors":[{"name":"Christophe Frémin","is_ca":true},{"name":"Sylvain Meloche","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.233354112101503,"gpt":0.5308665528212848,"spread":0.2975124407197818,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001049373,0.0009451835,0.001263654,0.001701244,0.0002813256,0.001116079,0.0009465746,0.001341631,0.004546742],"category_scores_gemma":[0.0006772407,0.0003850046,0.0004505317,0.001215953,0.0008129679,0.001462073,0.0006789523,0.00290552,0.003960428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001046653,"about_ca_system_score_gemma":0.001000258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005461249,"about_ca_topic_score_gemma":0.001102282,"domain_scores_codex":[0.9997777,0.00004680254,0.00002678928,0.00003871491,0.00008373235,0.00002610278],"domain_scores_gemma":[0.999726,0.0001078726,0.00003426426,0.00001342856,0.00007500208,0.00004337335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000150344,0.0001962789,0.0001474561,0.005768194,0.00005409776,0.0004109926,0.00006022737,0.0005443796,0.007499758,0.006980933,0.03286172,0.9453256],"study_design_scores_gemma":[0.00007705846,0.0002335597,0.0006099435,0.001421785,0.00005206429,0.001586603,0.00002945568,0.0001788283,0.002434534,0.003362255,0.9899961,0.00001784517],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004498267,0.9935092,0.000831885,0.001325656,0.0003862174,0.00002323323,0.00003068507,0.00003067518,0.003412601],"genre_scores_gemma":[0.002125588,0.9940251,0.0009546238,0.0007599545,0.0004065323,0.0000277471,0.00004348877,0.000005056626,0.001651969],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004546742,"threshold_uncertainty_score":0.01521033,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2756647112","doi":"10.1158/1535-7163.mct-17-0456","title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"MAPK/ERK pathway; Medicine; In vivo; Melanoma; Cancer research; Cancer; Pharmacology; Phosphorylation; Potency; MEK inhibitor; Targeted therapy; In vitro; Internal medicine; Biology; Cell biology; Biochemistry","authors":[{"name":"Ursula A. Germann","is_ca":false},{"name":"Brinley F. Furey","is_ca":false},{"name":"William Markland","is_ca":false},{"name":"Russell R. Hoover","is_ca":false},{"name":"Alex M. Aronov","is_ca":false},{"name":"Jeffrey J. Roix","is_ca":true},{"name":"Michael Hale","is_ca":false},{"name":"Diane M. Boucher","is_ca":false},{"name":"David A. Sorrell","is_ca":false},{"name":"Gabriel Martínez-Botella","is_ca":false},{"name":"Matthew J. Fitzgibbon","is_ca":false},{"name":"Paul Shapiro","is_ca":false},{"name":"Michael J. Wick","is_ca":false},{"name":"Ramin Samadani","is_ca":false},{"name":"Kathryn Meshaw","is_ca":false},{"name":"Anna Groover","is_ca":true},{"name":"Gary DeCrescenzo","is_ca":true},{"name":"Mark Namchuk","is_ca":false},{"name":"Saurabh Saha","is_ca":true},{"name":"Dean J. Welsch","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03944351150700175,"gpt":0.3106321426094479,"spread":0.2711886311024461,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003809346,0.0009435361,0.0005305328,0.0003338178,0.0002304177,0.000472496,0.0003602382,0.000418397,0.00117547],"category_scores_gemma":[0.0001047467,0.000246134,0.0004222299,0.0002185817,0.0001875421,0.0002900629,0.0001424285,0.0008760564,0.0004196633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005634564,"about_ca_system_score_gemma":0.0005332657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00131785,"about_ca_topic_score_gemma":0.002828817,"domain_scores_codex":[0.9998984,0.00001887553,0.000006659739,0.00001272538,0.00002175069,0.00004157152],"domain_scores_gemma":[0.9999497,0.000005955533,0.00001125202,0.000004727593,0.000008839031,0.00001960658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001978889,0.002121808,0.0005057161,0.0002579084,0.00006229045,0.0001598927,0.00004457552,0.001851335,0.9625018,0.0002806661,0.001293617,0.02894153],"study_design_scores_gemma":[0.001908473,0.03007114,0.006105844,0.00004141395,0.0001810784,0.001200452,0.00003933995,0.006343484,0.9449828,0.0001653803,0.008926813,0.00003382433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781169,0.009662995,0.004249087,0.0006553855,0.0001017022,0.0003848189,0.001237345,0.0004867751,0.00510507],"genre_scores_gemma":[0.9880355,0.0053371,0.002566573,0.0001176595,0.00002484969,0.0001566393,0.001264068,0.00003322717,0.002464413],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00131785,"threshold_uncertainty_score":0.004088163,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2258535515","doi":"10.1158/2159-8290.cd-15-1336","title":"Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma","year":2015,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":230,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust; Wellcome","keywords":"Melanoma; Precision medicine; Medicine; Personalized medicine; Liquid biopsy; Targeted therapy; Exome sequencing; Biopsy; Oncology; Cancer research; Exome; Internal medicine; Mutation; Bioinformatics; Pathology; Cancer; Biology; Gene","authors":[{"name":"María Romina Girotti","is_ca":false},{"name":"Gabriela Gremel","is_ca":false},{"name":"Rebecca Lee","is_ca":false},{"name":"Elena Galvani","is_ca":false},{"name":"Dominic G. Rothwell","is_ca":false},{"name":"Amaya Virós","is_ca":false},{"name":"Amit Kumar Mandal","is_ca":false},{"name":"Kok Haw Jonathan Lim","is_ca":false},{"name":"Grazia Saturno","is_ca":false},{"name":"Simon J. Furney","is_ca":false},{"name":"Franziska Baenke","is_ca":false},{"name":"Malin Pedersen","is_ca":true},{"name":"Jane Rogan","is_ca":false},{"name":"Jacqueline Swan","is_ca":false},{"name":"Matthew Ryan Smith","is_ca":false},{"name":"Alberto Fusi","is_ca":false},{"name":"Deemesh Oudit","is_ca":false},{"name":"Nathalie Dhomen","is_ca":false},{"name":"Ged Brady","is_ca":false},{"name":"Paul Lorigan","is_ca":false},{"name":"Caroline Dive","is_ca":false},{"name":"Richard Marais","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02417063816839317,"gpt":0.2713803003633998,"spread":0.2472096621950067,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002474257,0.0003771323,0.0002708105,0.0005600925,0.0002617989,0.0008805076,0.0003580973,0.0006189455,0.001213897],"category_scores_gemma":[0.002018889,0.0002324136,0.0002993893,0.0004263891,0.0006665324,0.0004846234,0.0006816162,0.0007319761,0.0004358206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004035752,"about_ca_system_score_gemma":0.0004961865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005293033,"about_ca_topic_score_gemma":0.0009621195,"domain_scores_codex":[0.9993749,0.0002280166,0.00005303116,0.000151444,0.0001536338,0.00003889252],"domain_scores_gemma":[0.9990397,0.0003268703,0.0001834382,0.0002493116,0.000146352,0.00005434222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0008114445,0.000233455,0.04286231,0.0002736953,0.0001175571,0.0004212891,0.0002320415,0.006758146,0.8625036,0.002191513,0.001220546,0.0823744],"study_design_scores_gemma":[0.00009882393,0.001490525,0.04312235,0.00009116442,0.0001889854,0.00350626,0.0002201869,0.03109137,0.8957158,0.004749723,0.01967242,0.00005231144],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.7704568,0.008858498,0.2092042,0.001288599,0.0002687676,0.0005421615,0.003223903,0.001134152,0.005022914],"genre_scores_gemma":[0.8560982,0.002489677,0.1370649,0.0003752379,0.0000690871,0.00025323,0.002381434,0.0001427496,0.00112541],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.002474257,"threshold_uncertainty_score":0.01308531,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4241605155","doi":"10.1016/j.ejca.2012.06.013","title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":229,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"Medicine; Ipilimumab; Melanoma; Guideline; Oncology; Vemurafenib; Internal medicine; Stage (stratigraphy); Systemic therapy; Adjuvant therapy; Skin cancer; Cancer; Surgery; Dermatology; Breast cancer; Immunotherapy; Pathology; Cancer research; Metastatic melanoma","authors":[{"name":"Claus Garbe","is_ca":false},{"name":"Ketty Peris","is_ca":false},{"name":"Axel Hauschild","is_ca":false},{"name":"Philippe Saïag","is_ca":false},{"name":"Mark R. Middleton","is_ca":false},{"name":"Alan Spatz","is_ca":true},{"name":"Jean‐Jacques Grob","is_ca":false},{"name":"Josep Malvehy","is_ca":false},{"name":"Julia Newton‐Bishop","is_ca":false},{"name":"Alexander Stratigos","is_ca":false},{"name":"Hubert Pehamberger","is_ca":false},{"name":"Alexander M.M. Eggermont","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02186877716028896,"gpt":0.2939923508756755,"spread":0.2721235737153865,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002322078,0.001296302,0.002397831,0.002697731,0.0004940677,0.000953445,0.002375394,0.003812597,0.001631286],"category_scores_gemma":[0.003652166,0.0005326147,0.00203143,0.002221023,0.0003336008,0.0008749061,0.0009091747,0.004140294,0.001612389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002056615,"about_ca_system_score_gemma":0.003478698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01485753,"about_ca_topic_score_gemma":0.03246199,"domain_scores_codex":[0.9984183,0.0003450516,0.0004013932,0.0001074439,0.0005722625,0.0001556233],"domain_scores_gemma":[0.9978238,0.0003927497,0.0003826932,0.00004551323,0.001132695,0.0002225797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003264138,0.0001962386,0.00251889,0.002937102,0.0002717228,0.0004676201,0.00005121051,0.001381605,0.001070883,0.0005868692,0.6701149,0.3200766],"study_design_scores_gemma":[0.0008736979,0.0003059271,0.03645222,0.01457024,0.001594166,0.005425284,0.0002086422,0.002373775,0.001778506,0.002299057,0.9339981,0.0001203629],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01022229,0.7900345,0.01214783,0.1173277,0.01480769,0.000838744,0.0116291,0.0007064664,0.04228572],"genre_scores_gemma":[0.08906148,0.656047,0.05388575,0.1002351,0.008220542,0.002308051,0.05845275,0.000431532,0.03135774],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01485753,"threshold_uncertainty_score":0.02954209,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3090469545","doi":"10.1200/jco.20.00995","title":"Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":227,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; McGill University; University of British Columbia; BC Cancer Agency","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Melanoma; Oncology; Internal medicine; Metastatic melanoma; Ipilimumab; Cancer research; Cancer; Immunotherapy","authors":[{"name":"Caroline Robert","is_ca":false},{"name":"Georgina V. Long","is_ca":false},{"name":"Benjamin Brady","is_ca":false},{"name":"Caroline Dutriaux","is_ca":false},{"name":"Anna Maria Di Giacomo","is_ca":false},{"name":"Laurent Mortier","is_ca":false},{"name":"Piotr Rutkowski","is_ca":false},{"name":"Jessica C. Hassel","is_ca":false},{"name":"Catriona M. McNeil","is_ca":false},{"name":"Ewa Kalinka‐Warzocha","is_ca":false},{"name":"Célèste Lebbé","is_ca":false},{"name":"J. Charles","is_ca":false},{"name":"Micaela Hernberg","is_ca":false},{"name":"Kerry J. Savage","is_ca":true},{"name":"Vanna Chiarion‐Sileni","is_ca":false},{"name":"Catalin Mihalcioiu","is_ca":true},{"name":"Cornelia Mauch","is_ca":false},{"name":"Ana Arance","is_ca":false},{"name":"Francesco Cognetti","is_ca":false},{"name":"Lars Ny","is_ca":false},{"name":"Henrik Schmidt","is_ca":false},{"name":"Dirk Schadendorf","is_ca":false},{"name":"Helen Gogas","is_ca":false},{"name":"Jesús Zoco","is_ca":false},{"name":"Sandra Re","is_ca":false},{"name":"Paolo A. Ascierto","is_ca":false},{"name":"Victoria Atkinson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02934943225884844,"gpt":0.3323646425640745,"spread":0.303015210305226,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001409882,0.0003554727,0.0007294021,0.0001645001,0.0002470215,0.0004645406,0.0002287925,0.0005426673,0.0007359982],"category_scores_gemma":[0.000708806,0.00009167093,0.0009248088,0.0001409218,0.0002857028,0.0003004181,0.0001651068,0.0007846368,0.0001197038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000476225,"about_ca_system_score_gemma":0.0003975783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005761162,"about_ca_topic_score_gemma":0.001429555,"domain_scores_codex":[0.9997154,0.0001363124,0.00001869798,0.00004220943,0.00003313352,0.0000542411],"domain_scores_gemma":[0.9995599,0.0000748393,0.0001375547,0.00002147272,0.00002634359,0.0001798885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5781552,0.01094673,0.1501248,0.0009763404,0.002908408,0.0004269033,0.0002080607,0.009112482,0.02355937,0.0003012103,0.004700197,0.2185804],"study_design_scores_gemma":[0.1216887,0.5810955,0.2769516,0.0002224335,0.002337067,0.0007627003,0.0001064339,0.004900011,0.005323123,0.0004013269,0.006154058,0.00005693356],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944724,0.004008486,0.0001747128,0.0001566612,0.00007009682,0.0001093857,0.0002178317,0.00001784773,0.0007726076],"genre_scores_gemma":[0.9979022,0.0007426638,0.000155176,0.0002988453,0.00008555498,0.0000750199,0.00041646,0.00000230773,0.0003219154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001409882,"threshold_uncertainty_score":0.007456303,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2022371765","doi":"10.2741/3003","title":"The RSK factors of activating the Ras/MAPK signaling cascade","year":2008,"lang":"en","type":"review","venue":"Frontiers in bioscience","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":222,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"MAPK/ERK pathway; Gene isoform; Ribosomal s6 kinase; Kinase; Cell biology; Biology; Signal transduction; Effector; Protein kinase A; MAPK cascade; Gene; Biochemistry; PI3K/AKT/mTOR pathway; P70-S6 Kinase 1","authors":[{"name":"Audrey Carrière","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0306186198857923,"gpt":0.2817528382859497,"spread":0.2511342184001574,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002537704,0.001233694,0.0007685035,0.001675476,0.0002710019,0.0008220354,0.0007562151,0.0007444847,0.002826088],"category_scores_gemma":[0.0002296024,0.0002662399,0.0003053582,0.001200952,0.0005380074,0.001125165,0.0005613862,0.001359059,0.00453927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006000315,"about_ca_system_score_gemma":0.0005792069,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005997767,"about_ca_topic_score_gemma":0.0009038829,"domain_scores_codex":[0.9998676,0.00001731907,0.00001353992,0.0000329488,0.00005450694,0.00001409791],"domain_scores_gemma":[0.9999298,0.00001679212,0.00001582227,0.000003822276,0.00002098803,0.00001276253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008633872,0.00005622053,0.0001780651,0.004659035,0.00004247477,0.0003544106,0.00005227722,0.0004150702,0.01020978,0.00610457,0.0148068,0.9630349],"study_design_scores_gemma":[0.00002079252,0.00005283285,0.0007872675,0.0004569205,0.00003142122,0.001856435,0.00003543344,0.0001136523,0.005056118,0.002296721,0.9892755,0.00001695025],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005976688,0.9926138,0.001004555,0.0002512195,0.0002360153,0.00001401609,0.00003323574,0.0000476189,0.005201943],"genre_scores_gemma":[0.003494122,0.9917858,0.0008828505,0.0001570141,0.0002005991,0.00002384707,0.00007622036,0.000004730001,0.003374735],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002826088,"threshold_uncertainty_score":0.00945425,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138718238","doi":"10.1523/jneurosci.5227-03.2004","title":"Mitogen- and Stress-Activated Protein Kinase 1 Mediates cAMP Response Element-Binding Protein Phosphorylation and Activation by Neurotrophins","year":2004,"lang":"en","type":"article","venue":"Journal of Neuroscience","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":222,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pediatric Oncology Group","funders":"National Institute of Mental Health; Medical Research Council; Merck KGaA; GlaxoSmithKline; National Institutes of Health; Pfizer","keywords":"CREB; Protein kinase A; Ribosomal s6 kinase; Cell biology; Mitogen-activated protein kinase kinase; Phosphorylation; Neurotrophin; Kinase; MAP kinase kinase kinase; Biology; Molecular biology; Transcription factor; Biochemistry; Protein kinase B; P70-S6 Kinase 1; Receptor; Gene","authors":[{"name":"Julian A. Simon","is_ca":false},{"name":"J. Simon C. Arthur","is_ca":false},{"name":"Amy L. Fong","is_ca":false},{"name":"Jami Dwyer","is_ca":false},{"name":"Monika A. Davare","is_ca":true},{"name":"E.A. Reese","is_ca":false},{"name":"Karl Obrietan","is_ca":false},{"name":"Soren Impey","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01271564260963545,"gpt":0.2392784170570495,"spread":0.2265627744474141,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008972056,0.000650283,0.0001945273,0.000195706,0.0002573743,0.0002265084,0.0001713379,0.0001665648,0.001243173],"category_scores_gemma":[0.0001323971,0.0001218442,0.0002041315,0.00007510984,0.0002142586,0.0002385231,0.000200841,0.0004641121,0.0004921704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004621165,"about_ca_system_score_gemma":0.0002783492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009208641,"about_ca_topic_score_gemma":0.001403625,"domain_scores_codex":[0.9999303,0.000008463492,0.00000349204,0.00001289599,0.00001901772,0.00002582139],"domain_scores_gemma":[0.9999516,0.000004652102,0.00001567426,0.000003618565,0.000006469518,0.00001805618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001042515,0.00001281941,0.00009193174,0.00004726593,0.000002099788,0.00004439957,0.00001013859,0.00007132697,0.9981145,0.0002015977,0.00004883957,0.001250903],"study_design_scores_gemma":[0.0000329467,0.0002448392,0.01419502,0.000020684,0.00001589031,0.0003945699,0.00003684131,0.001678019,0.9781925,0.0004801346,0.004698011,0.00001057793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902505,0.003897829,0.002440826,0.0001820668,0.0000430373,0.00001745916,0.0002308344,0.0001099398,0.002827453],"genre_scores_gemma":[0.9930862,0.002716175,0.001027411,0.00003373087,0.00001997573,0.00002913381,0.0003127795,0.000009670714,0.00276486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001243173,"threshold_uncertainty_score":0.004158854,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099267053","doi":"10.1101/gad.962902","title":"KSR is a scaffold required for activation of the ERK/MAPK module","year":2002,"lang":"en","type":"article","venue":"Genes & Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":220,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Montreal Clinical Research Institute","funders":"National Cancer Institute","keywords":"MAPK/ERK pathway; Cell biology; Scaffold protein; Biology; Caenorhabditis elegans; Kinase; Phosphorylation; Scaffold; Suppressor; MEK inhibitor; Signal transduction; Genetics; Cancer; Computer science; Gene","authors":[{"name":"François Roy","is_ca":true},{"name":"Gino Laberge","is_ca":true},{"name":"Mélanie Douziech","is_ca":true},{"name":"David Ferland-McCollough","is_ca":true},{"name":"Marc Therrien","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02668381207863523,"gpt":0.2261812319709946,"spread":0.1994974198923594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001147311,0.0004228943,0.0002353951,0.0002792807,0.0003787522,0.0004013538,0.000252669,0.0002785292,0.002276528],"category_scores_gemma":[0.0001712989,0.0002325194,0.0003067407,0.0001246919,0.0002490247,0.0003266783,0.0004654799,0.0003402765,0.002896785],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000439365,"about_ca_system_score_gemma":0.0002032461,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003855145,"about_ca_topic_score_gemma":0.0006502189,"domain_scores_codex":[0.9998378,0.0000153684,0.00001415445,0.0000424523,0.00005879536,0.00003147821],"domain_scores_gemma":[0.9998053,0.00001897321,0.00006782823,0.00003070705,0.00002147606,0.00005575271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00004776948,0.000008124625,0.0002831583,0.00002710436,0.00000304374,0.0002539902,0.00001152432,0.00004517068,0.9974101,0.0003200328,0.00004850429,0.001541377],"study_design_scores_gemma":[0.00001451739,0.00009303167,0.01260804,0.000008229821,0.00001261933,0.002281975,0.00003451702,0.001102141,0.9760885,0.0001832459,0.007562228,0.00001103915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873458,0.001309651,0.006787869,0.0001319989,0.00003388777,0.00001579405,0.0006233507,0.0005461641,0.00320552],"genre_scores_gemma":[0.9922621,0.0003261112,0.003050002,0.00002151704,0.00001032125,0.000006691737,0.001017567,0.00005363751,0.003252048],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002276528,"threshold_uncertainty_score":0.007615805,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120136426","doi":"10.1139/o04-121","title":"The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling","year":2005,"lang":"en","type":"review","venue":"Biochemistry and Cell Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":217,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canada Research Chairs; CancerCare Manitoba Foundation","keywords":"Chromatin remodeling; MAPK/ERK pathway; Cell biology; Histone H3; Chromatin; Biology; Signal transduction; Histone; Kinase; Mitogen-activated protein kinase; Phosphorylation; Protein kinase A; Chromatin immunoprecipitation; Cancer research; Gene expression; Gene; Genetics; Promoter","authors":[{"name":"Katherine Dunn","is_ca":true},{"name":"Paula S. Espino","is_ca":false},{"name":"Bojan Drobic","is_ca":false},{"name":"Shihua He","is_ca":false},{"name":"James Davie","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02077710537181383,"gpt":0.2729986952507849,"spread":0.2522215898789711,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002802374,0.0008667005,0.001113083,0.001721232,0.0003424074,0.0008423971,0.0007455645,0.001121323,0.003172474],"category_scores_gemma":[0.0002581036,0.0002896752,0.0002572388,0.001971871,0.0004797607,0.001177121,0.000501712,0.001144196,0.003869687],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007478198,"about_ca_system_score_gemma":0.0007663443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009484496,"about_ca_topic_score_gemma":0.002025583,"domain_scores_codex":[0.9999002,0.00001458834,0.00001140913,0.00002025624,0.00004133034,0.00001217093],"domain_scores_gemma":[0.9998971,0.00003328881,0.0000146538,0.000004767962,0.00003196231,0.00001819618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007555891,0.00007524798,0.000185501,0.008611802,0.00005171022,0.0003955157,0.00006720849,0.0003929801,0.0046719,0.00387286,0.03112321,0.9504766],"study_design_scores_gemma":[0.00001175586,0.00005121418,0.0006990939,0.0006986333,0.00002658703,0.001352463,0.00004740302,0.00005139433,0.0006271321,0.001715983,0.9947084,0.000009842598],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001781731,0.9971928,0.0001636329,0.0002213141,0.000259603,0.000005489421,0.00001501524,0.00001141931,0.001952566],"genre_scores_gemma":[0.0007041631,0.9971322,0.0001882237,0.0001448823,0.0001507315,0.000007411642,0.00003241134,0.000001285804,0.001638651],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003172474,"threshold_uncertainty_score":0.01061302,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2114067189","doi":"10.1158/0008-5472.can-13-2381","title":"ERKs in Cancer: Friends or Foes?","year":2014,"lang":"en","type":"review","venue":"Cancer Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":211,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Cancer; Medicine; Internal medicine","authors":[{"name":"Xavier Deschênes‐Simard","is_ca":true},{"name":"Filippos Kottakis","is_ca":true},{"name":"Sylvain Meloche","is_ca":true},{"name":"Gerardo Ferbeyre","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.207352210794642,"gpt":0.5086070552722703,"spread":0.3012548444776283,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007373323,0.0007365219,0.001062601,0.001447365,0.0004440067,0.001390288,0.0008923448,0.001547263,0.002911309],"category_scores_gemma":[0.0009881053,0.0002276568,0.000405305,0.001702325,0.00109327,0.003188598,0.0009282681,0.003236972,0.002290223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007258024,"about_ca_system_score_gemma":0.0008764351,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007407661,"about_ca_topic_score_gemma":0.00147159,"domain_scores_codex":[0.9998084,0.00005069817,0.00002144281,0.00003013235,0.00006616861,0.00002321242],"domain_scores_gemma":[0.9995919,0.0001965493,0.00003460082,0.00001821621,0.00009817463,0.00006064599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006981748,0.00004243619,0.0001764731,0.006344677,0.00006192757,0.0002433209,0.0001462908,0.000220777,0.0008132071,0.009189934,0.1037708,0.8789203],"study_design_scores_gemma":[0.000007066379,0.00002778718,0.0003140565,0.001398099,0.00002112744,0.0006939581,0.00008116712,0.00003295727,0.00009313697,0.004625822,0.9926955,0.000009412925],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005149974,0.9973953,0.00005214096,0.001344479,0.000525021,0.000001021339,0.000004783452,0.000004616291,0.0006210616],"genre_scores_gemma":[0.0006867649,0.9966149,0.0001008104,0.0007774107,0.0007500942,0.000002948729,0.00001033373,0.000002065798,0.001054646],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002911309,"threshold_uncertainty_score":0.00973928,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974404622","doi":"10.2741/3086","title":"The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases)","year":2008,"lang":"en","type":"review","venue":"Frontiers in bioscience","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":198,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Medical Research Council; Canadian Institutes of Health Research; European Commission","keywords":"Kinase; EIF4E; MAPK7; Mitogen-activated protein kinase; Cell biology; Translation (biology); Receptor tyrosine kinase; MAP2K7; Alternative splicing; Biology; Scaffold protein; MAPK14; Signal transduction; MAP kinase kinase kinase; Cyclin-dependent kinase 2; Biochemistry; Protein kinase A; Gene isoform; Gene; Messenger RNA","authors":[{"name":"Maria Buxadé","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02210076121847201,"gpt":0.2857966600787956,"spread":0.2636958988603236,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003237765,0.001515191,0.001046746,0.001869047,0.0002636988,0.001027159,0.0009563644,0.0008464939,0.003483462],"category_scores_gemma":[0.0002768483,0.0002512821,0.0002435575,0.002320824,0.0006819662,0.001785091,0.0006306653,0.001690153,0.00950327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006354628,"about_ca_system_score_gemma":0.0005904017,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005154263,"about_ca_topic_score_gemma":0.0007126976,"domain_scores_codex":[0.9998749,0.00001238677,0.00001718781,0.00002822342,0.00005136117,0.00001590089],"domain_scores_gemma":[0.9998629,0.00002834814,0.00003012086,0.000007540737,0.00003939467,0.00003158594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007783654,0.00005807403,0.0001535325,0.003547732,0.00003206369,0.00019131,0.00004077781,0.0003086861,0.005632333,0.003746222,0.03504142,0.9511701],"study_design_scores_gemma":[0.00001020342,0.00002182826,0.0002897267,0.000234064,0.00001192199,0.0006725691,0.00001763483,0.0000382442,0.0007461429,0.0009140896,0.9970372,0.000006414499],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003036241,0.9937171,0.0006146677,0.000247743,0.0005865587,0.00001141884,0.00004711603,0.0000537031,0.004418093],"genre_scores_gemma":[0.002206813,0.9892347,0.001138405,0.0002964263,0.0004329791,0.00002419966,0.0002086041,0.000007323317,0.00645061],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003483462,"threshold_uncertainty_score":0.01165336,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}